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 Abstract 
Aims: The aim of the thesis was to identify verbal descriptors of cancer induced bone pain 
(CIBP) and neuropathic cancer pain (NCP). An examination of the verbal descriptors 
associated with these two pain syndromes further considered the relationship between 
common verbal descriptors, cancer type, performance status and analgesia. 
Methods: The project was conducted in two phases; Phase one was a systematic review of 
the literature to examine current evidence of verbal descriptors in CIBP and NCP. Phase 
two utilised secondary data analysis methodology. Data from 120 patients with confirmed 
CIBP and 61 patients with confirmed NCP were deemed eligible for entry into a de novo 
database for secondary analysis. Key descriptive data were considered such as gender, 
ECOG and pain scores to characterise the patient population. Verbal descriptors of CIBP 
and NCP were considered in detail across the secondary de novo database.  
Results: Gender was not identified as a diagnostic characteristic of CIBP and NCP with 
similar distribution across prevalence of pain reporting and also pain severity.  Patients 
with breast (n=52,43.3%), prostate (n=35,29.2%) and lung (n=14,11.7%) cancer were found 
to be at an increased risk of CIBP. Those with NCP more was found more commonly among 
patients with breast cancer (n=21,34.4%).  Patients with CIBP were found to have an ECOG 
performance of 1 (n=49, 40.8%) or 2 (n=43, 35.8%) which was lower than those with NCP 
with an ECOG of 0 (n=32, 52.5%) or 2 (n=18, 29.5%). Comparisons were made across 
analgesia and treatment options for CIBP and NCP. Patients with CIBP received a greater 
variety of treatment options including bisphosphonates and radiotherapy while patients 
with NCP were more commonly treated with analgesia alone. Patients with CIBP and NCP 
were taking strong opioids, however those with NCP (n=45, 73.8%) were more likely to 
utilise strong opioids than those with CIBP (n=61, 50.8%). It was noted that those with NCP 
required a daily morphine equivalence of almost 50% higher than those with CIBP. Average 
consumption of opioids was 155.6mg, for patients with NCP, compared to 76mg in patients 
with CIBP. Common verbal descriptors of CIBP and NCP were identified. The most common 
verbal descriptors for CIBP were aching, gnawing and throbbing and the most common 
verbal descriptors of NCP were aching, tender and sharp. Of the most common 6 
descriptors for CIBP and NCP only one descriptor was unique to each pain type, gnawing 
for CIBP and stabbing for NCP. 
 
Conclusions: Patients with CIBP and NCP use similar verbal descriptors to characterise 
their pain with gnawing being unique to CIBP and stabbing being unique to NCP in the data 
considered within project. Further research is required to explore verbal descriptors which 
are both common and unique to CIBP and NCP. Further exploration of verbal descriptors 
would assist development of a comprehensive pain assessment tool which would enhance 
pain assessment for nurses, clinicians and patients.  
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Chapter 1.  
1.1 Introduction 
As medicine advances and treatment options improve, patients with cancer are 
living longer. Consequently, the patient population changes and cancer becomes 
similar to a chronic disease. As such the role of the healthcare provider must 
modify to reflect these changes (Little 2000).  
I have worked within oncology for almost twelve years. During this time, I have 
come to understand the enormous impact of poorly controlled cancer pain on the 
patient. It can adversely affect mood and exacerbate other symptoms, ultimately 
adversely affect quality of life. Family and caregivers often feel that death would 
be welcome when patients have difficult cancer pain (Coyle and Sculco, 2004). 
Figure 1 highlights the various aspects of daily living which can be adversely 
affected by poorly controlled cancer pain. 
Figure 1 - Consequences of cancer pain 
Cancer Pain
Healthcare costsHospitalisationsAnxietyDepression
ActivitySleep
Relationships
increases
decreases
Work
affects
Quality of life
 
The prevalence of cancer pain varies due to poor standardisation of assessment 
(IASP 2008). It is estimated that 50% of patients with cancer will experience pain 
during the early stages of their disease which rises to 75% in those with advanced 
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disease. In cancer, pain can be as a result of treatment, the cancer itself or 
unrelated causes such as pre-existing conditions (IASP 2008). 
The most common types of cancer pain are cancer induced bone pain and 
neuropathic cancer pain, hereafter described as CIBP and NCP (Caraceni and 
Portenoy, 1999, Nersesyan, 2007). It has historically been reported that the 
prevalence of CIBP and NCP, are 35% and 34% respectively (Grond S, 1996).  
Although CIBP and NCP are common, they are often difficult to manage (Grond S, 
1996). Whilst the majority of cancer pain can be effectively controlled in 80-90% 
of patients, CIBP and NCP are more difficult to manage effectively (WHO 1996). 
Standard analgesics can have limit of use as patients experience intolerable side-
effects at the doses required to relieve pain (Campbell, 2011). 
1.2 Personal experience 
Previously I worked as a palliative care research nurse with patients participating 
in clinical trials. These trials were investigating novel treatments for CIBP and 
NCP.  This position has afforded me the opportunity to assess the needs of this 
patient group and further allowed me to observe the adverse effects associated 
with pain treatments. I have, however, been surprised by the number of patients 
who experience considerable pain on a daily basis and accept this as part of living 
with cancer. I had not anticipated this level of acceptance amongst patients. From 
my experience many patients describe accepting pain as an inevitable compromise 
for living longer. One patient described pain as “I just accept nothing’s taking it 
away and I just have to put up with it.” Others feel pain is a constant reminder of 
the cancer, and some even feel pain may indicate the cancer is progressing. One 
patient became quite upset when describing her pain as she feels “On days when 
the pain is worse I’m sure it’s (the cancer) spreading”.  
I realised the importance of pain for the patient and considered if cancer pain 
such as CIBP and NCP, could be better managed. Clearly, this can only occur if 
pain is recognised and routine pain assessment encompasses this. Whilst health 
professionals tend to want patients to quantify pain (for example rate pain on a 
numerical rating scale e.g. 0-10, where 0 is no pain and 10 is the worst pain 
imaginable), such measures are less likely meaningful to patients. As CIBP and NCP 
are both common and difficult to treat it is imperative that these are identified 
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promptly.  Initial reading led me to the conclusion that there was a paucity of 
evidence regarding the assessment of CIBP and a moderate degree of evidence 
regarding the assessment of NCP. A number of studies have been conducted and a 
wealth of data on cancer pain has been collected, but data on verbal descriptors 
is less common. An accurate appreciation of verbal descriptors of CIBP and NCP 
would complement what is already known and perhaps enable nurses and other 
health care providers to enhance the clinical assessment of these difficult cancer 
pain types.  
1.3 Objective 
The overall objective of this study was to identify verbal descriptors of CIBP and 
NCP.  
1.3.1 Secondary objectives 
The study was designed to achieve this objective in two phases by examining the 
current evidence base on verbal descriptors of CIBP and NCP in phase one and 
through examination of a pre-existing dataset where information on verbal 
descriptors were available in phase two.  
 Secondary objectives were:  
1. Identification of the verbal descriptors more commonly associated with 
CIBP. This was achieved by conducting a systematic review of the existing 
literature in phase one (Chapter 5) and by performing an analysis of a pre-
existing dataset in phase two (Chapter 7). 
2. Identification of the verbal descriptors more commonly associated with 
NCP. This was achieved by conducting a systematic review of the existing 
literature in phase one (Chapter 6) and by performing an analysis of a pre-
existing dataset in phase two (Chapter 8). 
3. Examination of the relationship between pain intensity and gender, cancer 
type, performance status and analgesia in phase two through data analysis 
of a pre-existing dataset (Chapter 9). 
4. Examination of any common or unique verbal descriptors of CIBP and NCP in 
phase two through data analysis of a pre-existing dataset (Chapter 9).
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The study aims and design are summarised below in Figure 2; 
Figure 2 - Study schema 
 
1.3 An overview of CIBP and NCP 
The aim of this study was to examine the verbal descriptors of cancer pain types, 
CIBP and NCP. This section provides a brief overview of cancer pain with a greater 
focus on CIBP and NCP. 
1.3.1 Introduction 
In 2008 there were 309,500 new cases of cancer diagnosed within the UK ((CRUK), 
2011) and 156,000 deaths from cancer accounting for 37% of all deaths in the UK 
(W.H.O, 2009, CRUK, 2008). Patients with cancer often have many symptoms and 
a study of 1000 patients with advanced cancer showed that a median of 11 (range 
1-27) cancer-related symptoms were present (Walsh, 2000). These symptoms 
include nausea, fatigue, cachexia and pain amongst others; however, pain is the 
most common symptom. It is estimated that around 90% of cancer patients’ 
experience pain during their illness (Caraceni, 1999).  There are many causes of 
cancer pain and this can be related to the underlying disease or cancer treatment. 
Pain can be affected by psychological factors such as mood, anxiety or depression, 
it can adversely affect performance status and cause emotional and spiritual 
distress (Vainio, 1996, IASP, 2008). Although there are many types of cancer pain, 
Phase one Phase two 
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CIBP and NCP are the most common occurring in 35% and 34% respectively of 
patients with cancer-related pain (Caraceni and Portenoy, 1999, Grond S, 1996).    
Treatment of cancer pain is supported by the World Health Organisation (WHO) 
analgesic ladder, see Figure 3 (Azevedo Sao Leao Ferreira et al., 2006). It was 
developed in the early 1980’s and has been widely employed in the treatment of 
cancer pain. It is reported that, when used appropriately, 80-90% of cancer pain 
can be adequately controlled (WorldHealthOrganization, 1996). 
Figure 3 - WHO analgesic ladder 
 
  
Although cancer pain can be successfully managed using the WHO ladder, CIBP and 
NCP are more  difficult to control (Grond et al., 1999).  For CIBP and NCP, the 
effectiveness of analgesia is variable for each patient. Opioids are the mainstay of 
treatment however, their use can be limited due to adverse effects associated 
with higher dose levels. As such, clinicians often use opioids in combination with 
other medications to try and achieve better pain control. Anti-inflammatory drugs 
and adjuvant analgesics (e.g. antidepressants and anticonvulsants) are commonly 
used, however, based on numbers needed to treat adjuvant analgesics are 
effective in, at best, 1 in 3 patients (Finnerup et al., 2005). CIBP and NCP 
therefore represent common but difficult to control types of cancer pain. As these 
pain states have differences in the approach to management, it is fundamental 
that these are identified appropriately. This work examines verbal descriptors of 
CIBP and NCP however to enable a full appreciation of these pain states, key 
aspects of these will be discussed.    
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1.3.2 Study timescale 
This project was commenced in 2009 while working as a research nurse in a 
palliative medicine research team across a cohort of pain studies. Due to 
unforeseen personal circumstances I required to take a break in my studies 
between 2011 and 2014. Consequently, between 2009 and 2011 the project was 
designed, data were analysed and much of the background reading was 
completed. When the project was resumed to write-up in early 2015 the final 
writing of this thesis was completed.  
1.4 Cancer Induced Bone Pain 
Cancer spreading to bone is known as a bone metastasis and multiple cancer 
deposits in the bone(s) are herein described as bone metastases. Bone metastases 
are most common in prostate or breast cancer; 85% and 75% respectively (Nathan 
et al., 2005). They are also common in lung and renal cancer (40% and 25% 
respectively)(Nathan et al., 2005). Bone metastases can have a considerable 
impact on patient morbidity and mortality. Bone metastases which develop at 
multiple sites can cause multiple areas of pain and may ultimately affect bone 
marrow function (IASP 2009). Bone metastases can increase risk of fracture, 
increase potential to develop hypercalcaemia and also predispose to spinal cord 
compression (Healey and Tyler 2010). Some of these complications are potentially 
life-threatening. Advances in treatment of patients with metastatic disease have 
enabled patients to live longer. Patients with Breast and Prostate cancer which 
has metastasised to the skeleton can expect survival to be considered in terms of 
years, while patients with Lung cancer with bone metastases will have survival 
measured in months (Coleman, 2006). 
Metastatic bone disease can weaken the bone structure, such weakening can lead 
to pathological fractures and this is known to adversely affect the expected 
survival time (Hussain, 2001). For instance, patients with breast or prostate 
cancer, with a pathological fracture, can have a median survival of between 8 and 
12 months (Nathan et al 2005). Similarly, patients with primary lung disease may 
have a limited prognosis of around 4 months (Nathan et al 2005). It is notable that 
those with multiple bone metastases have a lower survival expectation than those 
with a single bone metastasis. Bone metastases therefore represent a clinically 
significant problem (Nathan et al., 2005). 
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1.4.2 Pathophysiology of CIBP           
Pain from bone metastases, CIBP, is the most common cause of pain in patients 
with cancer (Coleman, 2006). Bone metastases are reported to cause 30-35% of all 
cancer pain in patients with advanced cancer (Grond S, 1996). However, the 
presence of bone disease does not always mean the patient will have pain (Front 
et al 1979). A recent study by Koizumi et al of breast cancer patients with 
metastatic bone disease found 59.5% did not have pain (Koizumi et al., 2010). It is 
not yet established why bone metastases can be present, but yet the patient may 
not have pain.  
Animal models of CIBP have greatly increased our understanding of bone pain 
(Urch, 2004). In these animal models, cancer cells are implanted into the long 
bones of rodents to observe the pain behaviour. As well as allowing CIBP to be 
observed, the effects of medication can also be examined (Urch, 2004).  
Bone is a mineralized type of connective tissue but is not a static entity. It is 
made by osteoblast cells that construct the bone matrix but is constantly being 
broken down (resorped) by cells called osteoclasts (Urch, 2004). Therefore, within 
the bone there is a continuous process of construction and degradation. The 
balance of bone formation and resorption is delicate and subject to multiple 
influences. When cancer invades and grows within the bone, it affects 
osteoblast/osteoclast balance. Osteoclasts become activated resulting in the 
breakdown of bone, weakening its structure (Urch, 2004). Cancer cells also 
stimulate the release of cytokines and growth factors and this ultimately results in 
bone destruction (Goblirsch et al., 2005). 
Stimulation of nerve fibres also contribute to CIBP. Sensory afferent nerve fibres 
are responsible for conducting impulses from the periphery of the body to the 
spinal cord; these are found in large numbers within the bone and also in the 
outer layer covering the bone. It is believed that increased protein production 
occurs when cancer is present which then elicits a pain response. This pain can 
differ from mechanical pain because the bone structure may not be damaged 
(Urch, 2004). 
These animal models of CIBP have highlighted that CIBP is not simply mechanical 
pain from bone destruction; inflammatory and neuropathic processes are also 
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likely to be involved. Additionally, it has been shown that key central and 
peripheral nervous system mechanisms may too be involved. Different  areas 
within the brain are stimulated in response to painful stimuli in CIBP (Colvin and 
Fallon, 2010). There are also changes in the spinal cord which occur in response to 
CIBP with alteration in lamina within the dorsal horn.  A combination of multiple 
mechanisms contributing to the genesis of pain therefore highlighting the complex 
nature of CIBP.  
Bone metastases occur in either the axial or appendicular skeleton (Coleman, 
1997). The axial skeleton consists of 80 bones including skull, spinal column, ribs 
and sternum. Bone metastases are more common in the axial skeleton. The 
appendicular skeleton is composed of 126 bones; metastatic disease more 
commonly involves the humerus and femur (Healey, 2009). However, metastatic 
disease is less likely to affect the lower regions of the appendicular skeleton 
(Harrington, 1997). 
The area of pain can be caused directly by localised metastatic disease but it may 
also result from radicular pain in the spine. It is important to differentiate 
between direct or radicular pain as radicular pain may indicate impending 
compression of the spinal canal (Healey, 2009). Similarly patients with diffuse 
pain, within the appendicular skeleton, which worsens with weight-bearing or 
activities of living may be at risk of impending pathological fracture (Healey, 
2009).  
Assessment of CIBP usually requires a patient history and clinical examination 
followed by confirmation of the presence of bone metastases radiologically, a 
number of diagnostic imaging tools are available to assist clinical assessment of 
pain. 
1.4.3 Diagnostic Imaging Tools 
There are a number of imaging techniques which can enable the clinician to assess 
damage to bone and any progression of disease. The common techniques are 
highlighted for the purposes of understanding what a patient experiences and 
what is required for accurate assessment. 
Plain films, X-Ray - are a useful and cost-effective to assess any structural damage 
to the bone. They are limited as a diagnostic assessment as they can only detect a 
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lytic lesion (cancer) when there is a significant loss of bone density (30% cortical 
and 50% medullary).  
Computed Tomography (CT) -CT scans can be advantageous over plain films as 
they provide greater detail review of bone structure and areas of damage. It also 
gives more information than a plain film as it can identify any soft tissue invasion 
or an occult fracture (a fracture which does not show on plain x-ray).  
Bone scintingraphy (Bone scan) - Involves injecting a radioactive element held 
within a diphosphonate. Diphosphonates bind to the mineral matrix of the bone 
and the radioactive element helps highlight any area where cancer is stimulating 
new bone formation (Love, 2003). Bone scans detect metastatic bone disease in 
72-84% of cases however cannot determine any structural damage. They have 
limited use in aggressive tumours which inhibit new bone formation and this is 
necessary to make the scan effective (Healey, 2009). 
Further imaging techniques available are magnetic resonance imaging (MRI) and 
positron emission tomography (PET). However, these are most valuable when used 
in conjunction with the previously discussed imaging techniques. They are helpful 
when assessing soft tissue involvement but less helpful at assessing bone structure 
(Healey, 2009). 
Diagnostic tools such as CT, PET and Bone scans, are helpful to examine evidence 
of bone metastases, however they do not assess the intensity of pain or the 
impact of pain on the patient. For this to be achieved, a detailed clinical 
assessment is required. 
1.4.4 Presentation of Cancer Induced Bone Pain (CIBP) 
Cancer pain, and vis a vis CIBP and NCP, exists as a combination of background 
pain and breakthrough pain.  
Background Pain - “a constant or continuous pain of long duration” (Ferrell et al., 
1999). Background pain is characterised as continuous degree of pain which is 
often unrelenting. Areas of the skeleton more commonly associated with CIBP are 
the pelvis, femur, skull and vertebrae (Coleman, 2000).  
Breakthrough cancer Pain (BTcP) - “a transitory exacerbation of pain experienced 
by the patient who has relatively stable and adequately controlled baseline 
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pain.” (Portenoy et al., 2004). Patients with CIBP often have breakthrough pain 
(Laird et al., 2010a). It exhibits quick onset and short duration (less than 30 
minutes).  It can occur in response to movement particularly where pain is 
localised to weight bearing bones (volitional). It can also result from involuntary 
movements, such as coughing or breathing (non-volitional) as shown in Figure 4 
(Colvin and Fallon, 2010).  
 
Figure 4 - Breakthrough Cancer Pain (BTcP) 
 
 
 
In CIBP, the pain experienced by patients is not related to the primary tumour 
type (Coleman, 1997). It is not related to volume of disease or the patient’s age or 
gender. The development of CIBP results in a hypersensitivity state originating 
from the spinal cord. When this occurs nerves, which are not normally involved in 
pain transmission, (nerves responsible for light touch, vibration etc) become 
involved.  The patient then can  experience pain from non-painful stimuli 
(Coleman, 2000). It has associated altered skin sensation which is expressed as; 
 Altered sensation (paresthesia)  
 Pain from light touch (dynamic allodynia) 
  Pain from pressure (static allodynia)  
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 Pain from warm or cool stimuli (thermal hyperalgesia) 
These clinical features highlight the complex mechanisms that exist in CIBP and 
may result in the wide range of symptoms experienced (Healey, 2009). 
1.4.5 Treatment 
The aim of intervention and treatment of patients with all types of metastatic 
disease is to enhance quality of life and where possible prolong survival (Walsh 
and Hauser, 2006). This often requires management of several symptoms. For 
example; pain, poor mobility, impaired function, disease burden and low mood 
(Walsh, 2000). As such treatment can be multi-modal and require a number of 
interventions.  
CIBP can be mechanical in nature due to instability from bone destruction but it 
can also be caused by stimulation of afferent nerves. Surgery is typically utilised 
when the bone has sustained enough damage to risk a fracture or where a fracture 
has already occurred (Healey, 2009). Figure 5 - Pathological fracture below shows 
a pathological fracture in a plain film (X-Ray).  
Figure 5 - Pathological fracture  
 
(http://www.bhj.org.in/journal/2007_4902_april/images/379_fig3.jpg) 
Surgery can relieve CIBP by stabilizing the bone and reducing mechanical pain or 
simply by reducing the burden of disease. 
Pathological fractures are notoriously slow to heal and will usually require surgical 
intervention for long-term stabilization. Where possible, it is recommended to 
surgically fix the area prior to fracture, this reduces pain and the surgery is less 
complicated (Jawad and Scully 2010). For patients who experience pain, but 
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where the lesion does not pose risk of fracture or are perhaps are unable to 
receive surgical fixation, radiotherapy can provide symptomatic relief. 
Radiotherapy is the gold standard treatment for painful bone metastases. It is 
considered the most effective management for CIBP. However, studies have shown 
only 25% of those treated will have complete pain relief by four weeks following 
radiotherapy (McQuay et al., 2000). Other combinations of hormones, 
bisphosphonates, analgesia and chemotherapy can be employed to improve quality 
of life and prolong survival. 
Opioid analgesia are useful in the treatment of CIBP however the dose varies 
between patients and therefore treatment must be individualised. In some 
patients, to experience a response, they require escalated doses (Laird et al., 
2010b). Higher doses of opioids are linked with adverse side effects which 
therefore can limit their use. The WHO analgesic ladder advocate use of adjuvant 
analgesia such as non-steroidal anti-inflammatory (NSAIDs). Such adjuvants may be 
employed in treatment of CIBP although there is limited robust evidence to 
support NSAIDs use in treatment of CIBP (Laird et al., 2010b). 
Bisphosphonates can also offer analgesic benefit by strengthen bones affected by 
metastatic disease. They a bind to the bone matrix and are anti-resorptive. 
Studies have shown that this process can help reduce risk of pathological fracture, 
cord compression and for some patients, can reduce the level of pain experienced 
(Mantyh, 2002).  
1.5 CIBP Summary 
Cancer induced bone pain affects many patients with metastatic cancer and is one 
of the major causes of cancer pain. Patients who experience CIBP have an 
increased morbidity and reduced quality of life. CIBP presents a challenge in both 
its assessment and treatment. The treatment options for CIBP are wide and it is 
important that they are initiated appropriately. Accurate diagnosis of CIBP is 
essential and the examination of verbal descriptors presented within this MSc will 
assist with future assessment.  
1.6 Neuropathic Cancer Pain 
Neuropathic cancer pain is described as a direct result of a lesion or disease which 
affects the somatosensory system” (Treede et al., 2008). Neuropathic cancer pain 
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often starts as an acute pain but can develop into chronic symptoms, some causing 
disability (Gray, 2008).  
Approximately 40% of patients with cancer experience neuropathic pain and it can 
be a sign of disease progression (Caraceni, 1999, Bruera, 2003). Neuropathic 
cancer pain can be due to the direct effects of cancer (tumour compression) or as 
result of nerve damage caused by cancer treatment (such as surgery or 
chemotherapy) (Laird, 2008). 
1.6.1 Pathophysiology of NCP 
Neuropathic cancer pain is caused by damage to nerves which can lead to 
alterations in the peripheral and central nervous systems. Nerve damage can be 
caused by; 
 Chemotherapy (abnormal protein processing) 
 Direct tumour compression (ischaemia causing degeneration of axons) 
 Surgical (abnormal afferent nerve signalling) 
 Radiotherapy (Abnormal protein processing) 
Cancer treatment often involves the use of chemotherapy. Chemotherapy use can 
be limited due to a wide spectrum of adverse effects such as, nausea/vomiting, 
anorexia, alopecia, pain and neutropenia.  
Chemotherapies, both old and new treatments, are known to cause neuropathic 
cancer pain, most commonly peripheral neuropathy (Quasthoff, 2002). This is due 
to; 
 Chemotherapy molecules damaging the structure of peripheral sensory 
neurone 
 Chemotherapy induced inflammation of sensory fibres 
 Decreases growth factor level production in the brain  
These abnormalities cause increased central sensitivity by sending continuous 
erratic electrical signals. This increased sensitivity can manifest as pain when 
exposed to light touch such or in response to warm or cool stimuli. It can further 
  26 
cause muscle weakness or autonomic responses such as diarrhoea or sweating 
(Quasthoff, 2002).  
Anti-cancer treatments such as carboplatin, cisplatin, paclitaxel and thalidomide 
are just a few agents associated with development of neuropathic cancer pain 
(Quasthoff, 2002). The degree of neuropathic pain can be affected by the 
chemotherapy type, dose and number of chemotherapy cycles. Pain as a result of 
chemotherapy treatment can present as; Myalgia (Muscle pain), Arthralgia (Joint 
pain) or Sensory disturbances (Numbness, tingling, burning). Nerve damage can 
also be caused by direct tumour compression or surgical dissection which can lead 
to neuropathic pain, these will be explored to offer and understanding of the 
process of NCP. 
Neuropathic cancer pain can also arise when the surgical dissection damages the 
peripheral nerves or plexus. Post-surgical pain, such as post-mastectomy pain 
affecting axilla/chest wall can occur immediately following surgery or develop 
over a period of weeks to months or years (Tasmuth et al., 1996). 
1.6.2 Assessment of NCP 
Like all cancer pain, the assessment of NCP requires a comprehensive 
approach including a pain history with medical and neurological 
examinations (Jensen et al., 2007).  
A pain history should be inclusive of; locality, onset, duration, quality and 
intensity. Locality can be measured using a body chart or diagram and intensity 
can be measured by the patient on a numerical rating scale (For example select 
between 0 and 10, where 0 is no pain and 10 is the worst pain imaginable). 
Identification of the verbal descriptors of NCP would aid in assessing the nature of 
NCP which would facilitate comprehensive assessment. Comprehensive assessment 
of NCP should encompass measurable aspects such as pain duration, severity and 
impact on daily life (Jensen et al., 2007). 
Advances in assessment can assist in diagnosis of NCP. Development of sensory 
testing enhances examination of any change in sensitivity to touch, pinprick and 
hot/cold stimuli. It enables the clinician to compare responses in the affected 
area to an area of the body unaffected by pain (Finnerup and Jensen, 2010). As 
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patients with NCP often experience pain from non-painful stimuli, sensory testing 
can allow the clinician to map the area affected and allow assessment of any 
intervention effect. Assessment of NCP can be enhanced through nerve conduction 
studies, and diagnostic imaging such as CT or MRI scans. However, nerve 
conduction studies are more useful for large nerve fibre function assessment 
rather than small nerve-fibre neuropathies. Similarly CT and MRI scans are only 
diagnostic if there is a clear area of damage or tumour invasion in the affected 
area (Finnerup and Jensen, 2010).  
Patients often present with symptoms of sensory abnormality and pain which is 
characteristically similar to CIBP with a mix of background and breakthrough pain. 
Patients with NCP can often exhibit signs of sympathetic hyperactivity with 
excessive perspiration, changes in skin colour and temperature (Finnerup and 
Jensen, 2010). Patients may use terminology such as “burning”, “sharp” and 
“electric shocks” to describe their pain. 
1.6.3 Treatment 
Treatment of NCP is challenging because standard analgesics are often inadequate 
(Gilron et al., 2005). Combination of different analgesia, such as opioids, non-
steroidal anti-inflammatory drugs (NSAIDs), antidepressants, anticonvulsants and 
topical local anaesthetics are often utlised. Although there are various treatments 
available, these can be sub-optimal in a proportion of patients (Colvin, 2008). 
Strong opioids are limited by side-effects at the high doses required for analgesia 
(Laird, 2008).  
Adjuvant analgesics are drugs where the primary function is not analgesia but 
which can have an analgesic benefit. Common adjuvant analgesics used in NCP 
are;   
 Antidepressants- Tricyclic antidepressants and selective serotonin reuptake 
inhibitors (SSNRIs) have proven to have an analgesic effect at lower doses 
than required to provide antidepressant function. The use of 
antidepressants can however be limited in elderly patients or those with 
mental health issues (Portenoy and McDonald, 2006). 
 Anticonvulsants- second generation anticonvulsants, such as gabapentin 
and pregabalin, have been shown effective in NCP. Gabapentin and 
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Pregabalin stop the hyperactivity of neurones which cause the pain. These 
can be taken in addition to other medications and may synergistic with 
opioid medication, allowing lower doses to be used. Efficacy varies 
between patients and again their use can be limited in elderly patients or 
those with impaired renal function (Portenoy and McDonald, 2006). 
 Topical Lidocaine – Lidocaine is typically applied topically as a medicated 
plaster. The plasters suppress abnormal nerve behaviour without blocking 
electrical signals. Their use can be limited by mild skin irritation and it is 
contra-indicated for those taking class I anti-arrhythmic medications 
(Finnerup and Jensen, 2010). 
Other pharmacological interventions such as cannabinoids, weak opioids and 
topical treatments can be utilised in conjunction with other treatments for NCP 
but all have limiting efficacy and restrictions of use (Finnerup and Jensen, 2010, 
Finnerup et al., 2005). 
Due to the complex nature of NCP and the limiting aspects of some treatments, it 
is often beneficial to complement traditional treatment with non-pharmacological 
treatments to support the patient (Finnerup and Jensen, 2010). Patients with 
chronic pain, such as NCP, often have associated problems with lack of sleep, poor 
appetite, anxiety and depression. Cognitive behavioural therapy can help the 
patient develop coping mechanisms, relaxation techniques and distraction 
techniques. The use of cognitive therapy can be limited by availability and 
requires the patient to be a willing participant (Finnerup and Jensen, 2010). In 
extreme cases neurosurgery could be considered but is not always appropriate 
where survival and performance status are limited (Finnerup and Jensen, 2010).  
1.7 Assessment tools for CIBP and NCP 
A number of assessment tools are utilised in the assessment of CIBP and NCP. Two 
such tools are the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) 
and the McGill Pain Questionnaire (MPQ). 
The National Comprehensive Cancer Network (NCCN) advise in the Clinical 
Practice Guidelines for Adult Cancer Pain that a comprehensive approach to 
cancer pain assessment includes; 
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 Quantifying and characterising pain intensity and quality 
 Using patient-centred self-rating pain intensity scales (using numerical and 
visual aids) 
 Using patient descriptors of pain (burning, aching, shooting) (Lema et al., 
2010) 
It is important that any pain assessment tools use either some or all of these 
aspects. 
1.7.1 Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) 
The LANSS assessment tool has seven key elements (Bennett, 2001).  There are 
five core symptom assessments and two sections for clinical examination. The 
assessment is usually performed by a clinician as part of a clinical assessment 
using an interview technique. The LANSS is designed to determine if the patients’ 
pain is likely to be neuropathic in origin. It has been field tested as an assessment 
tool for neuropathic pain across many patient populations and varying 
nationalities and validated for use (Polit and Tatano Beck 2013). It has been 
further validated for use in distinguishing neuropathic pain from nociceptive pain 
(Bennett, 2001). The test is easy and quick to apply and has recently been 
developed further to allow self-report by patients. The test is scored out of 24, if 
the patient scores 12 or more it is likely that their pain has neuropathic 
mechanisms. In validity testing, the LANSS is considered accurate in discerning 
neuropathic pain from nociceptive pain in 4 out of 5 patients with chronic pain. 
While this is accurate, it is possible for those who score less than twelve to have 
an element of neuropathic pain. It should also be noted that the LANSS does not 
assess pain intensity or the impact of the pain on the patient’s function or quality 
of life. As such it should be used in conjunction with other assessments and form 
part of a comprehensive assessment (Bennett, 2007). 
1.7.2 The McGill Pain Questionnaire (MPQ) 
The MPQ was the first tool developed which used verbal descriptors in pain 
assessment (Towery, 1996). Previous research studies have shown its reliability 
and validity across large samples of patients with chronic pain (Mercadante 
1997b). The MPQ aims to elicit information from the patient on the locality, 
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intensity and behaviour of pain. The MPQ was seminal work, developed to allow 
patients to identify pain from a list of 78 words; which were believed to represent 
the multi-factorial nature of pain. These words included throbbing, shooting, hot-
burning or sharp (Melzack, 1975). The questionnaire consists of three main classes 
of word descriptors; sensory, affective and evaluative. These are used by the 
patient to describe their pain experience (Mercadante, 1997b). The MPQ features 
a diagram of the human body to enable the patient to record the location of pain 
and a category to allow patients to score their pain from no pain to excruciating 
(Melzack, 1975). A short-form was later developed with a set of 15 word 
descriptors, 11 sensory and 4 affective, Appendix 4. Patients can score the pain as 
none, mild, moderate or severe. The responses are scored on an intensity scale 
from 0-3 where 0 is none and 3 is severe (Melzack, 1987). Both versions of the 
MPQ can be used to evaluate pain and can be used over a period of time to 
monitor the effects of any intervention (Mercadante, 1997b). 
1.7.3 The Brief Pain Inventory (BPI) 
The BPI is a widely used multidimensional pain assessment tool which is utilised in 
cancer pain assessment. It has been validated for use among many differing 
cultures and languages (Cleeland, 2006). The BPI has been psychometrically tested 
for reliability, validity and sensitivity across various pain origins and for different 
languages to ensure consistent and reproducible results (Kumar 2011). The BPI is a 
self-report pain assessment tool with two key components – Intensity and 
Functional; 
Patients record intensity of their pain on a 0-10 numerical rating scale (NRS) 
where 0 is no pain and 10 is the worst pain imaginable. Patients are asked to score 
the severity of their pain at worst, least, on average and also at the time of 
completing the questionnaire. Additionally patients are asked to record pain 
location on a diagram of the human body (Cleeland, 2006). 
The BPI records the effect of pain on several aspects of daily life. Specifically how 
pain impacts on general activity, mood, walking ability, normal work, 
relationships, sleep and enjoyment of life (Cleeland, 2006). A similar 0-10 NRS is 
adopted here (0 is pain does not interfere and 10 pain completely interferes with 
that function). The BPI also asks the patient to assess the effectiveness of current 
analgesia in relieving their pain.   
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The LANSS, MPQ and the BPI are all validated tools and the LANSS and MPQ have 
been used in the work presented later.  
1.8 Summary 
CIBP and NCP are clinically challenging to diagnose and require a comprehensive 
assessment to ensure that appropriate treatment is initiated. Treatment options 
for CIBP and NCP can differ but are most effective when implemented when pain 
is acute. Early detection is therefore fundamental in treatment, and requires 
accurate assessment tools to assist clinicians. The work presented herein 
describes verbal descriptors of these pain states which will assist in prompt 
identification.  
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Chapter 2: The pain experience 
2.1 Introduction 
Chapter one described CIBP and NCP and outlined the importance of 
comprehensive assessment. This chapter considers the pain experience for the 
patient and will explore the challenges of pain assessment. It will further 
comment on standardisation of reporting pain as an outcome measure for clinical 
research.  
2.2 The Patient Perspective 
A qualitative study by Gibbins et al explored the patient perspective for aims of 
pain management in advanced cancer (Gibbins, 2014). They conducted interviews 
with 12 patients who had advanced cancer with the aim of identifying how this 
patient population determine when/if their pain is controlled and additionally how 
they communicate this to those health care professionals in pain management 
(Gibbins, 2014). Interestingly, their research found patients had more practical 
focus for pain management. Two of the four themes which emerged centred on 
the ability to reduce pain to a level which would allow the patient to resume 
normal daily activities and a level of independence. Ultimately, the patients 
wished to maintain their identity and their role within relationships (Gibbins, 
2014).  The study, while small in numbers, is far less emotive than anticipated. It 
offers valuable insight from the patient perspective, where pain assessment is 
recommended to focus on the pain impact on function rather than an NRS of worst 
pain. Therefore, focus assessment on what effect pain has on activities of living 
and then set goals for pain management with that issue as the focus. 
2.3 Assessment 
Pain assessment has been discussed, analysed and reviewed extensively but new 
techniques for assessment continue to emerge. There have been many pain 
assessment tools validated for use in general, or for more complex pain syndromes 
such as the LANSS for neuropathic pain as discussed in Chapter 1. The paper by 
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Phillips et al (2008) discussed the importance of reviewing the evidence on chronic 
pain when driving healthcare policy. They acknowledged key challenges of chronic 
pain particularly on economic and healthcare costs. They more importantly noted 
the adverse impact on quality of life of the individual (Phillips, 2008).  Although 
pain and pain assessment has been considered extensively in research and great 
improvements made to pain management, a number of people continue to 
experience pain as a permanent feature in daily life. It is often associated with 
anxiety, depression and loss of a sense of identity (Phillips, 2008). Within 
healthcare, policy and practice there is often focus on the caring dimension of 
nursing. It is encouraged that patients actively participate in their care. From 
clinical experience, anecdotally, many patients described a feeling of loss due to 
reduced physical function from chronic pain. It is from such experience the desire 
to improve pain assessment and management arose. It is important to determine if 
the validated tools such as MPQ and LANSS adequately define pain for the patient. 
Ultimately it would be exciting to lead policy in healthcare where pain is truly 
considered in a meaningful and accurate way for patients (McCaffery, 1983). 
2.4 Patient Experience 
Consideration of the patient experience is key to promote caring and dignity 
within health care. Work is emerging on emotional touchpoints which may 
facilitate the patient setting goals for healthcare professionals with pain 
management (Dewar, 2010). Patients can discuss their hopes, concerns, and 
desires about all aspects of care and could be readily applied in pain assessment 
and management (Dewar, 2010). Identifying key issues for patients may help set 
realistic targets. For example, performing daily tasks independently such as self-
care or playing golf or eating out with family. MacArthur described a three year 
longitudinal qualitative study which utilised emotional touchpoints in trying to 
embed compassionate care into 33 clinical settings of their local NHS facility 
(MacArthur, 2014). While the study findings are yet to be published. The 
presentation described that emotional touchpoints enabled patients to give real-
time feedback and to feel involved in their care. They found this encouraged staff 
to reflect on patient experiences and receive positive feedback for good practice. 
Additionally they described this improved staff confidence with relatives and care 
practices (MacArthur, 2014). Emotional touchpoints support the argument to use 
verbal descriptors in pain assessment. To ensure patient centred compassionate 
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care for patients with CIBP and NCP it is important to consider the emotional 
touchpoints in pain assessment. 
The patient perspective is important in pain assessment and development of new 
assessment techniques. Accurate identification of meaningful verbal descriptors of 
CIBP and NCP would support emerging work in emotional touchpoints of pain and 
encourage dialogue between the patient and caregiver to achieve daily goals for 
pain control. The following section will explore the measurement of pain within 
clinical trials. 
2.5 The measurement of the pain experience in clinical trials 
The International Association for the Study of Pain (IASP) describes pain as ‘An 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage.’ (IASP, 2011).  The key word 
in this statement is experience. Experience by the very definition is subjective 
and when this is applied to pain it underlines that pain is subjective and therefore 
a personal experience. 
2.5.1 Pain as a personal experience 
Pain is a personal experience; it can be difficult to measure. As the pain 
experience varies from person to person, it follows that measuring pain may be 
different between individuals and therefore challenging to measure. For patients, 
the pain experience is heightened by the persistent chronic nature and 
presentation.  
As highlighted in Chapter 1, CIBP and NCP can be difficult to assess. Assessment 
tools are required to meet the needs of as many users as feasible to ensure they 
are effective in identifying and discriminating between CIBP and NCP. It is widely 
accepted that pain assessment should be synonymous with good practice but a 
number of challenges have been identified (Gibbins, 2014); Lack of formal pain 
assessment; Difference between self-reported pain assessment and nurse pain 
assessment; Health care staff underrate patients pain. 
It is considered that the patient is the most reliable source and to consider pain as 
what the patient describes it as. As early as 1997 recommendations were made to 
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consider pain assessment as routine patient review just as one would record blood 
pressure or temperature (Gibbins, 2014).  
In pain assessment, nurses are often told pain is what the patient says it is 
(McCaffery, 1983). Many pain assessment tools are structured and aim to lead the 
patient to quantify and qualify their pain by predetermined parameters. These 
parameters are usually developed by textbook teaching and then validated by 
patients. There are a number of defined pain syndromes such as CIBP and NCP and 
more is required to be known about the patient experience of each. Such 
understanding would allow development of pain assessment tools designed with 
the patient at its core.  The challenge is how to effectively and accurately 
measure patient pain. 
2.5.2 Measuring pain 
It is important to measure pain for a several reasons; 
Patient- patient-centred care is a key goal of any healthcare interaction. Pain 
measurement allows insight into the pain experience of the individual. Pain may 
adversely affect quality of life therefore accurate pain measurement and 
assessment is key for the patient.  
Treatment efficacy- Consistent measurement of pain at regular time intervals can 
indicate efficacy of a pain intervention by assessing responses to individual 
therapies. 
Research- Pain measurement is important for research purposes, for example, 
assessment of new treatments or characterisation of pain.  
While it is important to measure pain for the reasons outlined above, there are a 
number of challenges linked to assessing each patient experience. Pain assessment 
tools, in common use, have been validated across a spectrum of patients of 
various pain types, social circumstances and medical history. Patients with chronic 
and acute pain, who have a life-limiting illness, are at heightened risk of being 
affected by physical or emotional disposition and also symptom burden of the 
illness. It is possible that the issue of standardised tools in this patient group may 
not directly compare to those who have received curative treatment or those who 
do not have a life-limiting illness. It is therefore important to measure pain in a 
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comprehensive and consistent manner where possible and to utilise validated 
assessment tools. 
2.6 Pain assessment tools 
There are multiple pain assessment tools validated for clinicians to utilise in 
practice. Assessing pain systematically affords the nurse insight into the patient’s 
pain experience and facilitate ongoing review of any intervention. Clinical 
environments which incorporate routine assessment techniques for symptom 
monitoring, particularly pain (Mock et al., 2000) are recommended. Due to the 
chronic nature of CIBP and NCP, they require any assessment to be comprehensive 
and to consider the multiple factors which can impact on chronic pain such as 
anxiety, depression, poor appetite and reduced quality of life (Benedetti, 2000). 
Healthcare professionals often utilise visual analogue scales or numerical rating 
scales which are simple to use and allow for interpretation of responses. The 
numerical rating system, (rating pain on a scale where 0 is no pain and 10 is the 
worst pain imaginable), complements the World Health Organisation analgesic 
ladder as referenced in Figure 3. Confusion arises when the system is adapted or 
varying versions are used among staff. For example, some VAS or NRS systems are 
numerical from 0-5; others ask the user to rate pain as mild, moderate or severe. 
Inconsistent approaches make it difficult for patients to answer uniformly and also 
make it difficult to draw conclusions or to offer comparisons against pain 
interventions. A single point pain assessment tool may not allow for the ‘whole’ 
experience of pain. Similarly use of one assessment may prove too rigid and not 
allow for the unique individual. Currently there is no widely utilised technique for 
implementing symptom assessment in the clinical environment. Further work is 
required to achieve a comprehensive, user-friendly and validated symptom 
assessment tool. 
2.7 Challenges of measuring pain 
Symptom assessment can be challenging due to the subjective nature of the 
symptom experience (Sykes et al., 1997). Advanced cancer can cause a diverse 
spectrum of symptoms. These symptoms feature physical and psychological 
components which the patient tries to convey to the assessing clinician. 
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Patient description can prove difficult as pain can mean different things to 
different individuals. As pain, among other symptoms, is a subjective and personal 
it is also multi-dimensional (Sykes et al., 1997). Pain can impact on physical and 
emotional function while having implications for family, work, social, spiritual and 
finance. Research into pain is notoriously difficult due to the dynamic process of 
pain and the multidimensional nature of pain, for a patient pain is constantly 
changing. Successful results must allow for the individuality of the research 
participants involved and how they measure the value of the assessed 
intervention. The same could be true for assessing efficacy of pain assessment 
tools. As discussed in Chapter 1, CIBP and NCP are types of chronic pain which 
patients often receive sub-optimal analgesia or experience adverse effects of high 
doses required to impact pain.  While pain assessment will often focus on severity 
and frequency, it is equally valuable to consider a variety of descriptors the 
patient associates with the experience. These descriptors offer insight into the 
impact of the pain on the quality of life of the patient. It may help indicate any 
anxiety, distress and impact on daily life. Therefore, assessment of pain should 
consider severity, frequency and the multi-dimensions of pain. For assessment to 
be valid, it must evidence reliability when repeated. Symptoms such as pain are a 
dynamic process and may change over time as such any assessment should assess 
for change. Similarly, pain research which express positive treatment outcomes 
often do not know the long term effects of the intervention. Others have applied 
rigorous outcome measures to allow dissemination of evidence and comparison 
across different groups.  
2.7.1 Pain assessment challenges in nursing         
Complex pain can be challenging to manage effectively; this is further impacted 
by increasing demand on nursing time and resources. Objective measurement 
tools such as a NRS are utilised to prompt patients to assess pain severity and for 
review of any effects of analgesia.   
Barriers to pain assessment include (Luckett, 2013); 
 Patient hesitant to report pain 
 Lack of knowledge by healthcare provider 
 Inadequate acknowledgment of pain by healthcare provider 
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 Misconceptions regarding strong analgesia such as opioids 
 Healthcare professionals desire for objective pain assessment 
A key, robust literature review by Luckett et al (2013) argue a belief among 
patients that objective pain assessment can lead to poor pain management 
through under treatment. They further describe that under treatment can be 
detrimental to the relationship between carer and patient. It is important to 
develop the relationship between the nurse, the patient and the family can afford 
the nurse a better understanding of the patient’s pain (Luckett, 2013). They 
suggest the relationship between carer, patient and family may improve pain 
assessment and management. Luckett et al (2013) suggest potential in nurse 
prescribing to reduce delay in pain treatment.  
2.8 Study design- standardising outcome measures for pain 
Standardisation of outcome measures should be applicable over varying research 
projects and allow for different patient backgrounds and a variety of past medical 
histories. During development of pain research studies into pain assessment, a 
number of key recommendations can be utilised to assist the researcher in trial 
design. The Initiative on Methods, Measurement and Pain Assessment in Clinical 
Trials (IMMPACT) developed a consensus framework for key considerations of trial 
design for pain as an outcome in research (Dworkin, 2010). Since 2002 a varied 
group from different specialties have held consensus meetings on pain. The group 
includes, among others, experience from nursing, oncology, pharmacology, 
surgery and psychology (Dworkin, 2010).  
IMMPACT describe key outcome measures which should be considered when 
designing pain trials involving patients, including participant pain, physical and 
emotional needs. Standardisation of approach and comprehensive outcome 
measures may allow for direct comparison across multiple study populations 
(Dworkin, 2010). Comparative information is necessary to enable researchers to 
compare and contrast sample groups which feature different types or stages of 
disease and even those with differing demographics.  
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2.8.1 Participant disposition 
Participant disposition is a motivating factor when consenting to take part 
research; in work previously completed, a key area of interest was patient 
attitudes toward research in advanced cancer (Todd, 2009). In palliative medicine 
research there are many ‘gatekeepers’ in the form of clinicians, health care staff 
and family. Often these ‘gatekeepers’ considered clinical trials with this patient 
population as burdensome and those with advanced cancer were ‘too vulnerable’ 
or ‘too unwell’. What the review found was rather contrary to this opinion and 
many wished to be considered for clinical trials for altruistic reasons as they did 
not wish others to ‘suffer’ as they felt they were and others wished to participate 
as it renewed ‘hope’ for an improvement in symptom burden (Todd, 2009). These 
motivations may also make participant disposition of the patient group differ from 
another sample population. It may also affect translation of finding as makes the 
issue of standardising and comprehensive outcome measures ever more relevant 
(Todd, 2009). 
Considering patients who have advanced cancer and chronic CIBP or NCP as a 
unique patient population is potentially inaccurate, perhaps pain is unique to each 
individual and it might be impossible to directly compare one to another. 
However, these patients offer an insight to debilitating pain which is likely to 
reduce quality of life, this is so important as they have a life-limiting illness where 
clinicians and nurses measure goals by quality, not quantity. Improvement of pain 
has the potential to greatly improve quality of life and as such requires accurate 
and prompt assessment and effective intervention. 
2.9 Summary 
Pain is challenging to assess due to the subjective nature of an individual 
assessment. There is not a single assessment tool that can effectively assess all 
patient groups and all different pain experiences. Some may be more 
discriminatory than others and some assist with assessment of pre/post 
intervention. While these challenges exist it is important, when designing research 
studies on pain, to ensure outcome measures can be expressed across varying 
populations. It is only possible to synthesise results if the questions and 
approaches become standardised. The following chapter will consider the 
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methodology utilised in performing the secondary analysis of patients with CIBP 
and NCP. 
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Chapter 3:  Literature pertaining to the Methods 
3.1 Phase one: Systematic Review Methodology 
Systematic review is a robust examination of evidence on a given topic.  A 
comprehensive systematic review aims to assess all available literature on that 
particular subject using a clearly defined search strategy (Lichtenstein, 2008). It 
combines many individual studies to answer important clinical questions. For 
example, one study of a particular drug or treatment may not be sufficient to 
support its efficacy but a number of studies which prove the same outcome may 
defend its use.  
Research in healthcare has gathered momentum following advances in technology 
as users worldwide could access large volumes of information quickly and 
conveniently (Houde, 2009). This makes evidence based medicine more accessible 
but incorporating this into nursing practice requires an understanding of the 
research process and the value of the evidence. Some research is considered 
stronger than others which are illustrated below in Figure 6.  
Figure 6 - Evidence hierarchy (Mazel and Pullman 2011) 
 
Systematic reviews are located at the top of the evidence hierarchy as they are 
considered the cornerstone of evidence-based practice. They lead to the 
development of guidelines and policy to provide consensus of the best practice 
and care of patients (Loke, 2007). Within palliative medicine, rationale for 
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common practice is often based on evidence from expert opinion or case series 
and case reports. There is little evidence in this field which is derived from 
original research such as randomised controlled trials or cohort studies. Therefore, 
systematic reviews of the evidence are limited in this speciality due to the 
restrictive number of randomised controlled trials and cohort studies.  
Systematic reviews are combined findings from a number of primary evidence 
sources (Smith, 2011). Primary evidence is sourced from original research which 
has involved research participants. Secondary evidence is usually systematic 
reviews, or meta-analyses which lead to clinical protocols/guidelines. Such 
secondary evidence (e.g. systematic reviews) enable multiple sources of research 
and evidence to be summarised. Systematic reviews help draw conclusions based 
on multiple studies and offer trends while also express conflicting results across 
different studies (Smith, 2011). Such a technique allows identification of what is 
already known on a subject when seeking to answer a research question.  
Effective performance of a systematic review requires an understanding of the 
research process. At least one author requires experience of reviewing literature 
to allow for an appropriate search strategy, there also should be an experienced 
researcher who will be involved in the process of inclusion and exclusion of 
articles. A systematic review of the literature can achieve desired goals when 
applied in a systematic and robust manner. A tool can be utilised to assist the 
researcher with the process of performing a systematic review such as the SIGN 
guideline number 50 (SIGN, 2008). 
The first step in a systematic review is to develop an important clinical question 
which is believed to have not yet been answered. Following this the primary 
author should seek to collaborate with at least one other researcher to ensure the 
review of the literature is comprehensive and robust. The authors should have a 
similar interest and develop the key question to assess what is currently known on 
the topic, they should ensure that there is no similar review recently published. 
The authors must develop a protocol or plan which will be used to perform the 
review, this must contain; 
 Defined eligibility criteria for inclusion or exclusion of articles or research 
are identified and the rationale for these explained. 
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 Devise a clearly defined search strategy and offer support for why these 
were chosen, including the different literature databases and any journals 
to be hand searched. 
 Identify keywords and phrases utilised in the search and the rationale for 
why these keywords should capture the most appropriate articles. 
 Results should include reference to any independent review and discussion 
with peers. Any use of guidelines to assist this should also be documented. 
 Conclusions should be justified according to the literature reviewed. 
A variety of techniques and tools can be utilised to assist an author when 
considering what they wish to include in the search strategy (Holly, 2012). It is 
important to consider key aspects of research being included for example; what is 
the patient population (e.g. disease type, disease status, gender specific), What 
were the interventions- (e.g. effectiveness of treatment, assessment tools), what 
were the comparatives groups (e.g. comparing gender, age, social status) and 
what were the outcome measures (e.g. effect of patient, effect on care).  
3.1.2 PRISMA diagram (Preferred Reporting Items for Systematic Reviews and 
Meta-analyses) 
The value of a systematic review, as with any research, is providing transparency 
of the review process to allow peer appraisal and to evidence rigour of approach. 
A PRISMA diagram can assist with clarity of approach by displaying articles 
searched, considered and excluded at varying stages of a systematic review 
(Moher et al 2015).  
3.1.3 Systematic review: Advantages and disadvantages 
A systematic review encourages a transparent search strategy and rationale for 
inclusion and exclusion of keywords and articles. This allows duplication of the 
research process by another author and increase the validity and reliability the 
results (Chandler, 2013). A systematic review is only as good as the search 
strategy utilised by the author(s). However, if performed in a robust and 
systematic manner the author(s) can achieve sufficient results to answer the 
research question and gain an understanding of much what is known, or not 
known, on a key area of interest which will help direct future research. 
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3.1.4 Systematic review: Peer review 
Systematic reviews are a scientific process and as such should evidence efforts to 
minimise bias and reduce risk of reporting error. Peer review can increase rigour 
when determining inclusion and exclusion criteria for data synthesis within a 
systematic review. Discussion with a peer on which fulltext records are to be 
included, or excluded, in data synthesis can help reduce decision influenced by 
prior experience or knowledge (McDonagh et al 2013).  
3.2 Rationale for secondary analysis 
Secondary analysis is the analysis of data or information collected by another 
researcher or for a different purpose than the secondary analysis proposed; it can 
be most easily defined as ‘second hand’ analysis rather than a primary data 
collection more common place in research. 
Primary data collection is where information is obtained from research 
participants to answer a specific research question. This can involve a number of 
researchers over a period of time utilising a number of data collection techniques 
such as surveys, questionnaires, interviews or through observation (Pollack, 2001). 
Performing primary data collection can be time consuming and prove expensive. In 
times of austerity researchers are increasingly considering secondary data analysis 
to gain new knowledge from previously collated data (Aponte, 2010).  
3.2.1 Prevalence of secondary analysis   
Studies performed by Aponte (2010) and Smaldone and Connor (2003) identified 
181 studies within nursing research which utilised secondary analysis between 
1997 and 2008, of which 34 were performed on large data sets. This is a smaller 
number of studies than expected given the nine-year period considered. There are 
a number of reasons why secondary analysis is not a more common methodology in 
nursing research. It may be through lack of knowledge or understanding of how to 
perform secondary analysis. It may result from limited access to primary data sets 
or the data sets may be incomplete. Consideration should be given to the 
potential advantages and disadvantages to secondary analysis. Research has been 
performed in the health service for a number of years with the aims of improving 
quality, accessibility and delivery of care (Huston, 1996).  
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As previously described, secondary analysis uses existing data to explore new 
research questions or methods (Magge, 2006). This methodology enables data 
which were intended for one purpose to potentially be utilised for another 
(Pollack, 2001). Secondary analysis can be performed on a number of resources 
such as patient charts, surveys or databases.  
3.2.2 Advantages and disadvantages of secondary analysis 
A key advantage of secondary analysis is cost-effectiveness. As the primary data 
collection has already been achieved, the investigator is not required to perform 
questionnaires, interviews or similar (Windle, 2010). A misconception is that 
secondary analysis saves the researcher time. While there is no primary data 
collection, the researcher may expend a number of hours understanding the 
primary methodology and the variables involved. It can be further delayed where 
data are missing or incomplete. Original sources may feature design flaws or 
inaccurate data analysis. Such difficulties can be overcome where the researcher 
performing secondary analysis has access to the primary dataset or to the 
investigator who performed the original study (Windle, 2010). These difficulties 
could provide a rationale for the limited use of secondary analysis as a research 
method. While secondary analysis can prove challenging there are many 
advantages to performing secondary analysis.  Data sets can comprise large 
sample sizes which increases the researcher’s ability to answer research 
questions. The data being examined can be longitudinal which will further enable 
the researcher to identify trends and changes over a period of time (Nicoll, 1999). 
It is helpful for the researcher should have an understanding of the topic and the 
purpose for which the primary data were collected to ensure they maximise 
potential of secondary analysis. While it may save efforts of primary data 
collection, secondary analysis can prove time consuming where data is incomplete 
or requires extraction (Aponte, 2010). Understanding must be given to the primary 
data collection methods, how the data were coded and entered onto the database 
to limit errors in the secondary analysis. 
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3.2.3 Ethical issues of secondary analysis  
As with all research, ethical consideration applies to using secondary data 
analysis. Typically, patients are advised during the informed consent process that 
their data may be looked at in the future for further analysis. Secondary data are 
likely to be free from any identifying information but researchers should always 
check with local ethics boards to ensure further ethical approval is not required 
(Windle, 2010, Fisher, 2002). Many support the argument that ethical approval is 
not always required for secondary data analysis (Huston and Naylor 1996) 
(Tripathy 2013). They argue that secondary data analysis is an observational study 
and there is no contact with the participant and no new data are collected. 
However, if the analysis requires access to confidential information, such as 
patient records, the investigator must seek the appropriate approval (Tripathy 
2013). 
3.3 Summary 
The two methodologies utilised within this MSc are systematic review of literature 
and secondary analysis. Systematic review of the literature, provided its 
conducted in a robust manner, can provide much of what is already known on a 
particular topic. Secondary analysis is a useful technique for interrogation of data 
already gathered and can positively contribute to nursing knowledge and 
literature irrespective of the time since data collection.  
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Chapter 4: Methods 
4.1 Introduction 
Chapter 3 considered the methodology of systematic review and secondary data 
analysis. This chapter presents the research objectives of this MSc. It further 
describes the methods and datasets which were utilised to meet the objectives. 
4.2 Research objective 
Identify verbal descriptors of CIBP and NCP. 
4.2.1 Secondary Objectives 
1. Identification of the verbal descriptors more commonly associated with 
CIBP (Chapter 5 and Chapter 7).  
2. Identification of the verbal descriptors more commonly associated with 
NCP (Chapter 6 and Chapter 8).  
3. Examination of the relationship between pain intensity and gender, cancer 
type, performance status and analgesia (Chapter 9)  
4. Examination of any common or unique verbal descriptors of CIBP and NCP 
(Chapter 9) 
 
Study design 
Phase one Phase two 
Systematic review – Verbal 
descriptors of CIBP 
Raw data extraction (multiple 
databases) and de novo database 
creation 
Systematic review – Verbal 
descriptors of NCP 
De novo database analysis 
 
The research question was answered through a combination of systematic review 
and secondary analysis. The MSc was therefore conducted in two distinct phases: 
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Phase one was an examination of current literature on common verbal descriptors 
of CIBP and NCP, as detailed in Chapters 5 and 6. Following an understanding of 
current evidence, a de novo database was created and analysed. 
 
4.3 Phase one: Systematic review of the literature 
A systematic review was considered as the most effective method to understand 
evidence on verbal descriptors of CIBP and NCP, as discussed earlier in 3.1.3. To 
ensure a comprehensive review of the literature, as a novice researcher, peer 
review was sought throughout to ensure maximum potential to capture what is 
already known about verbal descriptors of CIBP and NCP. The peer review is 
discussed below and will be evidenced within systematic review chapters. 
Discussion with one supervisor was undertaken at the beginning of this MSc. During 
these meetings, keywords were identified and databases were selected which 
were considered relevant for the information sought. This was to ensure keywords 
would capture appropriate articles and that rigorous search was conducted. An 
adaptation of SIGN 50, Appendix 3, was utilised to focus on key areas as 
recommended in 3.1, which also facilitated discussion on which articles should be 
included in review. Key areas of focus were; the patient population, the 
assessments conducted and any consideration of verbal descriptors.  Following a 
number of searches and reading, further discussion was undertaken as follows; 
1. Abstract review – discussion focused on the articles selected for abstract review 
to confirm potential relevance to the project and for agreement on those to be 
selected for full text review. 
2. Full text review – articles selected for full text review were considered 
independently using a checklist adapted from the SIGN guidelines appraisal tool 
for systematic reviews. Discussion followed to achieve consensus on articles for 
inclusion. 
This peer review allowed for quality check of articles selected and helped reduce 
bias through preconceived ideas. 
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4.3.1 Phase one: Systematic Review - search strategy 
A comprehensive systematic review was undertaken where a number of electronic 
databases were searched including; Medline (1996-2010), Embase (1996-2010), 
British Nursing Index (1994-2010) and the Cochrane Database of Systematic 
Reviews (2010). Keywords and combination phrases were agreed with one 
supervisor in advance of search. In addition to an electronic search particular 
journals were hand searched including; Palliative Medicine, the European Journal 
of Palliative Care and the Journal of Pain and Symptom Management. All 
subheadings were included and results were limited to the English language and 
studies which involved humans.  
4.4 Phase two – Secondary analysis 
Phase two of the study was a secondary analysis of a raw data from three research 
studies involving cancer pain assessment, see Table 1. 
Table 1: Secondary Analysis 
Phase two 
Process Output 
Data selection from 3 raw datasets  
 
 
1. Identify common descriptors of CIBP and 
NCP within literature 
Data extraction  5. Identify if pain severity reported as higher 
among CIBP or NCP cohorts 
6. Identify if there is a higher opioid 
requirement among CIBP or NCP cohorts 
De novo database design 
Analysis of De novo database 
 
 4.4.1 Data selection process 
A large volume of raw data were accessed from three anonymised datasets. These 
datasets were screened to identify suitable patient data for the purposes of 
identifying verbal descriptors of CIBP and NCP. It was expected that a number of 
patients would not contain sufficient relevant data relevant to meet the key aims 
of this study, for example recording of verbal descriptors. It was anticipated that 
100 patients would be eligible for inclusion in the secondary analysis due to the 
participant numbers across the three studies. Primary eligibility for inclusion 
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within phase two, secondary analysis, was that the participants had to have 
participated in one of the following three studies: 
 
Table 2: Studies utilised for De Novo database 
Study Title Type No. 
Participants 
A Characterization of physical properties of bone 
pain using the McGill Pain Questionnaire, the 
Brief Pain Inventory, Breakthrough Pain 
Questionnaire and Somato-sensory Testing 
Cross-
sectional 
survey 
135 
B Development of a systematic approach to assess 
the sensory, cognitive, affective and functional 
components of cancer induced bone pain CIBP 
characterization 
Observational 59 
C Ketamine in Pain Study; double-blind 
randomised controlled trial of Ketamine vs. 
placebo for patients with neuropathic pain in 
cancer patients 
Randomised 
controlled 
trial 
214  
 
Study A. Characterization of physical properties of bone pain using the McGill Pain 
Questionnaire, the Brief Pain Inventory, Breakthrough Pain Questionnaire and 
Somato-sensory Testing. 
This was a cross-sectional survey (Jekel et al 2007) of patients who attended a 
large regional oncology unit (Edinburgh) between 2003 and 2004. A convenience 
sample (Polit and Tatano Beck 2013) of one hundred and thirty-five patients 
(n=135) with CIBP or NCP were assessed to provide individual detailed pain 
characterization. All patients consented, in study A, to provide demographic data, 
treatment history and current medication. Patients completed baseline 
assessments regarding their pain which included the MPQ and the BPI. Additional 
assessments were completed including a breakthrough cancer pain questionnaire 
and quantitative sensory testing (QST) to offer further characterization of pain. 
QST allows assessment of small nerve endings through a thermal threshold test 
and also assessment of large nerve endings through vibration assessment. Data 
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were anonymised and stored on an excel spreadsheet. Study A was a useful study 
for inclusion in the secondary analysis undertaken in phase two. It was deemed 
useful, despite the small scale, because consideration was given to characterising 
pain in patients with CIBP and NCP, it further captured verbal descriptors. It was 
however, a single site convenience sample of 135 participants, therefore a small 
scale study and limiting transferability (Polit and Tatano Beck 2013). It had a 
limited recruitment period of twelve months, which would account for the small 
sample size, however the rationale for this recruitment period was not given. 
Despite these limitations this was a very useful dataset for inclusion in the de 
novo database due to the patient cohort and assessments applied.  
Study B. Development of a systematic approach to assess the sensory, cognitive, 
affective and functional components of cancer induced bone pain 
characterization.  
Study B was an observational project to assess a number of characteristics of CIBP 
pre and post palliative radiotherapy. It followed a pre-post intervention design 
(Harris et al 2006) to validate assessment of CIBP and included patients with CIBP 
who were attending a regional oncology unit (Edinburgh) in 2008 for palliative 
radiotherapy to bone metastases. Fifty-nine patients (n=59) (34 Female, 25 Male) 
with a median age of 63 years (range 38 years to 88 years) completed both pre 
and post (6-8 weeks later) radiotherapy treatment assessments.  The most 
common primary cancers were breast (52.5%) and prostate (25.4%) which would be 
expected in patients attending for palliative radiotherapy for CIBP, as described in 
chapter 2. The baseline assessments included demographic data, anti-cancer 
treatment history and current analgesia. Patients also completed BPI, SF-MPQ and 
quantitative sensory testing (QST).  This was a small scale study as it was 
undertaken as part of a higher degree, this also accounts for the nature of the 
recruitment period. The data were included, despite this, because the patient 
population had clearly defined CIBP and therefore representative of the patient 
population sought for this secondary analysis. Additionally, verbal descriptors of 
CIBP were captured within a comprehensive baseline assessment. This 
comprehensive assessment increases understanding of the patient pain experience 
which is beneficial when performing a secondary analysis on raw data. 
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Study C. Ketamine in Pain Study; double-blind randomised controlled trial of 
Ketamine vs. placebo for patients with neuropathic pain in cancer patients.  
Study C comprised patients who attended two regional cancer centres (Glasgow 
and Edinburgh). The Ketamine in Pain Study commenced recruitment in 2008 and 
remained open to recruitment where final accrual was anticipated at 214 patients 
(n=214). The study was a double-blind randomised controlled trial (Polit and 
Tatano Beck 2013) which examined the effects of Ketamine vs. Placebo on 
patients with neuropathic pain. Patients were recruited to the Ketamine in Pain 
study with a clinically confirmed neuropathic pain related to cancer or cancer 
treatment. All patients consented to provide demographic data, treatment history 
and current analgesia information. Patients also completed the sf-MPQ, EuroQol 
(Quality of Life Assessment), Distress Thermometer, Hospital Anxiety and 
Depression self-assessment (HADs), Leeds Assessment of Neuropathic Symptoms 
and Signs Pain Scale (LANSS). Of those patients who had already completed the 
Ketamine in Pain Study, raw data from 31 were included in this secondary data 
analysis. As this DB RCT remained open to recruitment at the time of this 
secondary analysis the results from the data used stand alone would not provide 
generalizable results. However, it was a multi-centre study using a number of 
validated pain assessment tools and the data from Study C increased the number 
of data in the NCP cohort to enable similar sample sizes for the CIBP and NCP 
datasets. Of note the data used in this secondary analysis were baseline data and 
therefore no intervention from investigational medicinal product 
4.5 Phase two: Data selection 
Anonymised, raw a data was utilised for the secondary analysis. Identification of 
relevant patient data key inclusion and exclusion criteria were developed to be 
applied across all studies. The criteria were developed following discussions with a 
statistician for robustness of data extraction; 
4.5.1 Inclusion criteria 
 Patient written informed consent to participate in study A, B or C 
 Patients with incurable cancer 
 Complete baseline assessments 
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 Worst pain score (VAS 0-10) 
 Average pain score (VAS 0-10) 
 Complete McGill Pain Questionnaire  
 Analgesia history 
 Key demographics 
 Clearly defined CIBP or NCP 
4.5.2 Exclusion criteria 
 Patients receiving neo/adjuvant therapy 
 Incomplete assessments  
 Indistinct pain definition (mixed pain) 
Anonymised, raw data were screened from studies A, B and C according to the 
above inclusion and exclusion criteria. A number of those who met all inclusion 
criteria were then excluded due to partial or incomplete data following discussion 
with the statistician. 
The de novo database was developed from two datasets as illustrated in Figure 7 
and Figure 8, 
Figure 7 - CIBP dataset 1 
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Figure 8 - NCP dataset 2 
 
4.6 Phase two: Secondary analysis - data extraction 
Data extraction, in this secondary analysis, involved raw data from three studies 
which made identification of common data important. As mentioned, guidance 
was sought from a statistician to ensure all data were appropriately considered. 
This was to minimise bias in patient selection. Discussion was undertaken to 
ensure agreement for any data deemed not to meet criteria for inclusion 
secondary analysis. From discussions with the statistician, a new database was 
designed to allow transcription of uniform data which were common to all. These 
parameters were; 
1. Demographic data 
2. Opioid medication 
3. Pain intensity 
4. McGill Pain Questionnaire 
 
Phase Two Parameters 
 
1. Demographic data: Key information was extracted on patients including age and 
gender. This was to allow characterization of the patient population.  
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2. Opioid medication: Patients received a number of different strong opioid 
analgesia with varying doses. Following discussion with study supervisors it was 
decided to enter the data and apply a conversion to a morphine equivalent daily 
dose (MEDD). The rationale for this was it would allow for direct comparison 
across the patients. 
3. Pain intensity: While patients had completed a number of different pain 
assessment tools, all patients had data available on worst pain and average pain 
on a numerical rating scale (NRS) of 0-10 where 0 is described as no pain and 10 is 
considered the worst pain imaginable. 
4. McGill Pain Questionnaire: The MPQ was performed across all studies in two 
different formats; the long form (lf) and the condensed short form (sf) version. 
While both tools are validated the information is captured differently. The 
database was therefore designed to capture common descriptors to both versions 
to allow direct comparison across the patient groups. 
Once common data were extracted and entered onto the database it was then 
analysed according to the aims and outcome measures described below. 
4.7 Phase Two: Secondary analysis - Outcome measures 
The de novo database comprising data from studies A, B and C was analysed with 
the aim of answering the research question while also considering key secondary 
objectives; 
1. Identify if pain severity reported as higher among CIBP or NCP cohorts 
2. Identify if there is a higher opioid requirement among CIBP or NCP 
cohorts 
4.8 Phase Two: Secondary analysis -  Summary 
A number of patients, who had previously participated in clinical studies which 
assessed CIBP or NCP, were considered for inclusion in the secondary analysis. 
Particularly patient data where pain scores and verbal descriptors were recorded. 
As the secondary data analysis utilised data from three different studies with 
varying researchers, a database was designed to collect relevant information 
pertaining to the aims of this research. The following chapters will present the 
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data collected for patients with CIBP and NCP respectively. Any findings will be 
presented and discussed in later chapters. 
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Chapter 5: Phase One – Systematic review of verbal descriptors of Cancer 
Induced Bone Pain 
5.1 Introduction 
As discussed in Chapter 1, Cancer Induced Bone Pain (CIBP), is the most common 
source of cancer-related pain. CIBP affects approximately 30,000 patients per 
year within the United Kingdom (Kane, 2015).  Bone metastases are present in 60-
84% of cancer patients, more typically with breast, lung and prostate cancer. Bony 
metastases can develop extensively throughout the skeleton however they are 
most common within the spine (Shaiova, 2006).  CIBP is associated with increased 
morbidity and can often result in hospital or hospice admission. CIBP adversely 
affects mobility, mood, quality of life and pose an increased risk of pathological 
fractures (Kane, 2015). 
In 50% of new diagnoses of bone metastases, pain is the presenting symptom. 
Typically, this pain increases over a period of weeks to months and is usually well 
localised. Patients may use particular words to describe their pain and these 
words can provide diagnostic identifiers of the underlying pain type (Mercadante, 
1997a). 
Traditional textbook teaching describes CIBP as a dull ache which can become 
exacerbated when pressure is placed on the area, for example during ambulation, 
sitting or standing (Kane, 2015). Currently the clinical descriptors for CIBP are 
based on dictum rather than a strong evidence base. As descriptors used by 
patients vary widely, the diagnosis of CIBP is usually only made in the presence of 
supporting radiological evidence.   
Validated descriptors for CIBP would inform the clinician, assist with accurate 
assessment of pain and guide radiological investigations. Early detection of CIBP is 
likely to have a significant impact on the quality of lives of patients and enable 
treatment to commence at the earliest opportunity (Kane, 2015).  
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5.2 Systematic review CIBP: Aim 
The aim of this systematic review was to explore the available literature on the 
characterisation of CIBP, namely the descriptors most commonly associated with 
this pain syndrome. 
5.3 Systematic review CIBP: Search Strategy 
A comprehensive literature search was undertaken. The following databases were 
examined electronically: British Nursing Index (1994-2010), the Cochrane Database 
of Systematic Reviews (2010), Embase (1996-2010) and Medline (1996-2010). The 
search terms used were “Cancer” AND “Bone” AND “Pain” AND “Descriptors” AND 
“Assessment” AND combinations of these”. Eligible studies had to examine verbal 
descriptors of cancer induced bone pain. Following independent abstract review 
by two researchers, relevant articles were appraised using a systematic review 
checklist, Appendix 3, adapted from the Scottish Intercollegiate Guidelines 
Network ((SIGN), 2008). Additionally, the following journals were hand searched: 
Palliative Medicine, Journal of Pain and Symptom Management, and the European 
Journal of Palliative Care. All subheadings were included. Results were limited to 
English-language journals and studies involving humans. 
5.3.1 Inclusion Criteria 
Articles were selected if they included patients with cancer who had clinically 
proven cancer induced bone pain of any tumour type. Studies were required to 
assess patient descriptors of pain using a recognized method such as interview or 
assessment tool. Articles were included until two researchers could reach 
agreement on full review. 
5.3.2 Exclusion Criteria 
Articles were excluded if they did not meet all inclusion criteria or if they did not 
present original material.  
As expected, the literature search produced a number of articles. The titles were 
reviewed and if deemed potentially relevant, were examined further. Due to the 
broad search terminology a number of irrelevant articles were retrieved. 
Subsequently 52 abstracts were reviewed, and where relevant for the purposes of 
this review, selected for further analysis. Some articles examined treatment of 
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pain rather than pain assessment and other involved patients with non-malignant 
disease. Where eligibility was unsure, following discussion, the article was 
reviewed in full. Eight articles were reviewed in full and two were deemed 
appropriate for inclusion in the review as agreed by two researchers. The final 
literature search was performed on the 27th October 2010 and the results are 
displayed in the Prisma diagram below; 
Figure 9 - Prisma Diagram - Systematic review CIBP 
 
 
5.4 Systematic review CIBP: Results  
Fifty-two articles were identified of which two met all eligibility criteria and 
agreement for inclusion. The key findings from each study were identified and 
discussed and the key comparators are highlighted in Table 3; 
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Table 3: Systematic review - CIBP 
Authors Study type No. of participants Key findings 
Laird et 
al 2010b 
Cross-sectional 
survey 
55 Verbal descriptors: Annoying, 
Gnawing, Aching, Nagging 
Kerba et 
al 2010 
Cross-sectional 
survey 
98 17% expressed neuropathic 
features Neuropathic features 
expressed higher worst pain 
 
5.4.1 Cross-sectional survey (Laird et al 2010b) 
Laird et al (2010b) conducted an exploratory study examining the characterisation 
of CIBP (Laird et al., 2010b). It was a cross-sectional survey (Polit and Tatano Beck 
2013) of 55 participants in one regional cancer centre. All patients had a clinical 
diagnosis of CIBP with supportive radiological evidence such as an X-ray or CT scan 
(Laird et al., 2010b). Patients were excluded if the pain mechanism was unclear, 
although it was not discussed if agreement was sought when mechanism unclear. 
The site of pain had to correspond to an area known to be affected by bone 
disease. Data were collected on patient demographics, past medical history and 
medication. A single interview was conducted. All patients completed a number of 
questionnaires, the Brief Pain Inventory (BPI), the McGill Pain Questionnaire (MPQ) 
and a tool specifically designed to identify breakthrough pain (Laird et al., 2010b). 
Of the 55 patients included in the study 58% were inpatients and 42% outpatients. 
The majority had advanced cancer, 11% had a single bone metastasis, 46% had 
multiple bone metastases and 26% had multiple metastases. The vertebrae in the 
spine were the most common site of pain. Many of the patients (38%) were taking 
strong opioid analgesia for their pain with a daily dose morphine equivalent of 
68mg. From the MPQ the most common descriptors (in 89% of patients) were 
selected from the “dullness” section (sore, hurting, aching, heavy). The descriptor 
most commonly selected was annoying in 42% (n=23). Others descriptors 
frequently selected were gnawing (38%), aching (38%) and nagging (38%). The 
patients had a median average pain score of 4 and a median worst pain score of 7 
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(0-10 NRS) (Laird et al., 2010b). This was a small convenience sample from one 
centre, this limits the transferability of results however it considered key aspects 
of CIBP, including verbal descriptors (Polit and Tatano Beck 2013). It was a 
valuable study as it conducted a comprehensive assessment of CIBP and offered 
characterisation of the pain therefore it merited inclusion in this systematic 
review.  
5.4.2 Cross-sectional survey (Kerba et al 2010) 
Kerba et al (2010) performed a prospective cross-sectional survey in a tertiary 
regional cancer centre (Polit and Tatano Beck 2013). Ninety-eight consecutive 
patients were consented to the study. All patients had been referred for palliative 
radiotherapy for metastatic bone pain (Kerba et al., 2010). Patients were given a 
physical examination, as per usual practice, and past medical history was 
obtained. Data were collected on analgesia and other pain treatments. Patient 
assessments included; 
 BPI (Brief Pain Inventory) 
  S-LANNS (Self-report Leeds Assessment of Neuropathic Symptoms and 
Signs)  
 EORTC (European Organisation for Research and Treatment of Cancer)  
 Quality of Life Questionnaire (version 3) 
Assessments were performed at baseline and then 4-6 weeks later, a pre-test, 
post-test design (Polit and Tatano Beck 2013). Of the 98 patients recruited, the 
median age was 62 years. There was equal distribution across gender (male n=51, 
female n=47) (Kerba et al., 2010) which offers equal representation across gender. 
A number (n=11) of primary cancer sites were found, more commonly breast 
(34%), prostate (28%) and non-small cell lung cancer (11%), this would be typical 
of cancers which would feature CIBP. Many of the patients (n=75) were taking 
strong opioid medication equivalent to 45mg of morphine. The study found that 
17% of patients with bone pain had neuropathic features in their pain (S-LANSS of 
≥ 12, criteria indicative of neuropathic pain) (Kerba et al., 2010). Those patients 
with neuropathic elements reported a higher worst pain on a numerical rating 
scale (where 0 is no pain and 10 is the worst pain imaginable) of 8.3 (SD1.7) 
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compared to a worst pain of 7.0 (SD 2.0) (NRS) in those who did not. This is a 
valuable study as they identified an expression of neuropathic features through 
comprehensive assessment of CIBP. Similar to the study by Laird et al (2010b), the 
study by Kerba et al (2010) was a convenience sample within one centre which 
would limit transferability. The sample size was small but did include a 
comprehensive pain assessment on patients with varying types of advanced 
cancer, therefore generalisability is limited but it does add meaningful 
characterisation of this patient population. This study was further deemed 
suitable for inclusion as it noted a number of patients, with CIBP, to express 
neuropathic descriptions and features on assessment.  
5.5 Discussion 
Only two studies met all criteria for inclusion in this review, this suggests that 
verbal descriptors of CIBP remain an under-researched area. The study by Laird et 
al (2010b) was the first characterisation study of CIBP to be undertaken and 
provides useful insight into the impact of CIBP on the patient. Of the included 
participants who reported an average pain score (on an NRS of 0 to 10), the 
median value was 4/10. The study further showed exacerbations in CIBP with the 
median worst pain reported as 7/10. The work by Kerba et al (2010) was included 
for the purposes of this review as it met the criteria however it also complements 
the findings of study one. Laird et al (2010b) identified descriptors more 
commonly associated with neuropathic cancer pain in patients with proven CIBP. 
While Kerba et al (2010) also found evidence of descriptors, more typically 
associated with neuropathic pain, present in patients with CIBP. This suggests 
traditional teaching of NCP and CIBP may not be entirely accurate. Additionally, if 
neuropathic features in CIBP are more common than anticipated, perhaps 
treatment of CIBP requires adjuvant analgesia more commonly associated with the 
treatment of NCP. Both studies are limited by small study populations however 
raise important issues regarding the current understanding and assessment of 
CIBP. Both studies acknowledged further research is required. 
5.6 Limitations 
As results were limited to two studies, any interrelation or generalisability of 
results are restricted. There were few results which met inclusion criteria despite 
the broad search terms, suggesting this to be an under researched area.  Of the 
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two included studies interpretation of results is limited due to the relatively small 
participant numbers. Similarly, the limited number of results suggest further 
research is required to characterise verbal descriptors of CIBP associated with this 
pain state. 
5.7 Further reading 
Due to a break in studies, the literature search for this chapter was most recently 
undertaken on the 27th October 2010, it was, therefore, deemed important to 
perform a further literature search for any information published on verbal 
descriptors of since undertaking this MSc. To ensure consistent methodology, the 
same search strategy and limitations were applied. The following databases were 
comprehensive searched and examined electronically: British Nursing Index (2010-
2015), the Cochrane Database of Systematic Reviews (2015), Embase (2010-2015) 
and Medline (2010-2015). The same search terms were used, (“Cancer” AND 
“Bone” AND “Pain” AND “Descriptors” AND “Assessment” AND combinations of 
these). The final search was undertaken on the 30th July 2015. There were 253 
titles examined, 23 abstracts considered and 8 articles read in full. Elements of 
the new literature identified through this updated search were incorporated into 
chapter 1 and 2, however, no further studies were found to meet the inclusion 
criteria for the data analysis. This reinforces the currency of this work despite the 
timeframe involved. 
 5.8 Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
In literature, CIBP is typically described as ‘dull’ or ‘aching’ but it has also been 
associated with descriptors such as ‘annoying’ and ‘gnawing’ which are typically 
used to describe neuropathic pain. The two studies included in the review 
identified some descriptors more commonly associated with NCP. From the limited 
number of studies which met the criteria for inclusion in the review, it is evident 
that verbal descriptors of CIBP have not been examined in a robust, systematic 
fashion. It is therefore recommended that future studies are required to identify 
verbal descriptors of CIBP. The studies included highlighted some descriptors more 
typically linked with neuropathic cancer pain and Chapter 6 explores verbal 
descriptors of NCP in greater detail. 
  64 
 
Chapter 6: Phase One – Systematic review of verbal descriptors of 
Neuropathic Cancer Pain 
6.1 Introduction 
As discussed in Chapter 1, around 40% of patients with cancer will experience 
neuropathic cancer pain either as a direct result of cancer or damage caused by 
anti-cancer treatments (Caraceni and Portenoy, 1999, Laird, 2008). Neuropathic 
cancer pain (NCP) is described as “pain arising as a direct consequence of a lesion 
or disease affecting the somatosensory system.” (Treede et al., 2008). Damage to 
nerves can lead to alterations in the peripheral, central and autonomic nervous 
systems. The alterations send abnormal electrical signals which results in 
increased sensitivity within the central nervous system. Patients can experience 
spontaneous pain with varying degree of duration and intensity (Finnerup and 
Jensen, 2010).  
Neuropathic pain in cancer is particularly difficult to diagnose as patients typically 
exhibit inflammatory, neuropathic, ischemic, infiltrative and compressive 
components and often involves multiple sites (Lema et al., 2010).  As the 
autonomic nervous system is also affected by NCP, it can cause dizziness, altered 
bowel habit or urinary retention (Paice, 2003).  
NCP is particularly burdensome because onset and duration is unpredictable. It 
can be elicited through non-painful stimuli, which is described as allodynia 
(Finnerup and Jensen, 2010). For example, a patient can experience pain from 
simple acts such as putting on clothing or in response to warm or cool stimuli. A 
simple action of a warm shower or exposure to cold weather can evoke a pain 
response. These unique features of NCP can negatively impact on the daily life of 
the patient and considerably reduce quality of life (Finnerup and Jensen, 2010). 
As discussed in Chapter 1, treatment of NCP is a clinical challenge. Common 
treatments and medications can have limited success and the high doses required 
to affect pain often have intolerable side effects (Farrar et al., 2001). 
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Traditional textbook teaching describes neuropathic pain as “burning” “stabbing” 
or “pins and needles”. However, it is important to identify if these results are also 
true for patients with neuropathic cancer pain. This chapter explores what is 
known on verbal descriptors of NCP through a systematic review literature. 
6.2 Systematic review NCP: Aim 
The aim of this systematic review was to examine available literature on verbal 
descriptors of neuropathic cancer pain. 
6.3 Systematic review NCP: Search Strategy 
A comprehensive literature was undertaken where a number of electronic 
databases were searched including; Medline (1996-2010), Embase (1996-2010), 
British Nursing Index (1994-2010) and the Cochrane Database of Systematic 
Reviews (2010). In addition to an electronic search particular journals were hand 
searched including; Palliative Medicine, the European Journal of Palliative Care 
and the Journal of Pain and Symptom Management. Searching terminology was 
“Neuropathic pain” AND “Cancer” AND “Descriptors” AND “Assessment” and a 
combination of these. All subheadings were included. Results were limited to the 
English language and studies which involved humans. Eligible studies were 
required to examine verbal descriptors of neuropathic cancer pain. Following 
consideration of sixty-seven article titles, 25 abstracts were reviewed 
independently by two researchers using a systematic review checklist, Appendix 3. 
6.3.1 Inclusion criteria 
Articles were required to include patients with a clinical diagnosis of neuropathic 
cancer pain irrespective of tumour type. Additionally, there must be assessment 
of patient descriptors of pain by a recognised methodology such as an interview or 
validated tool. Where eligibility was unsure, following discussion, the article 
was reviewed in full. 
6.3.2 Exclusion criteria 
Articles were excluded if they did not meet inclusion criteria and also if they did 
not present original material. 
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6.4 Systematic review NCP: Results  
The literature search returned a number of articles, see Figure 10. Twenty-five of 
which were deemed eligible for further examination. Examination of titles and 
abstracts generated through literature search were performed independently by 
two researchers. Discussion between the researchers enabled a shortlist of 11 
articles for review in full, where opinion differed the article was reviewed in full.  
Of the 11 articles reviewed, 3 were included for the purposes of this review. 
Others were excluded for a number of reasons; Some were review articles; others 
were not focused on the cancer patient population. The final literature search was 
performed on the 21st January 2011. The key findings were identified and 
discussed as follows; 
Figure 10 - Prisma Diagram – Systematic review NCP 
 
 
A summary of key features of the three articles selected for inclusion in this 
chapter have been displayed in Table 4; 
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Table 4: Review of verbal descriptors of NCP 
 
6.4.1 Secondary analysis (Wilkie et al 2001) 
Wilkie et al (2001) performed a secondary analysis, as discussed in Chapter 4, of 
data collected from 123 patients between 1988 and 1996 across three western 
states in America. The patients included were those who had previously 
participated in studies of lung cancer pain. All patients had a diagnosis of lung 
cancer; the majority of patients, 90%, had non-small cell lung cancer (Wilkie et 
al., 2001). The stage of disease varied from stages I to IV however the majority of 
patients were stage IV (50%) or stage III (35%). Suggesting only 15% of patients did 
not have metastatic disease. All patients included had complete demographic data 
and McGill Pain Questionnaires (Wilkie et al., 2001). Patients also completed the 
Lung Cancer Etiology Tool (LCET) specifically designed for the purposes of their 
study. The LCET is a data list of 11 nociceptive and 14 neuropathic defining pain 
sites to clearly identify what type of pain was being assessed.  
Study type Secondary analysis 
Wilkie et al 2001 
One-day prevalence 
Holtan & Kongsgaard          
2009              
Observational                     
Manfredi et al., 2003 
No. of 
participants 
123 453 187 
Key cancer 
site(s) 
Lung only Gastrointestinal              
Haematological                
Lung 
16 different primary cancers 
Key verbal 
descriptors 
Aching                     
Exhausting                  
Tiring                           
Tender                   
Throbbing  
Aching                           
Stinging                         
Burning   
Burning                          
Electrical                                
Cold                             
Tingling                                  
Pins & Needles                   
Numb 
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Key findings: 
 Four hundred and fifty-seven (457) pain sites were reported by 123 
patients  
 Patients had a median of 4 pain sites  
 Twelve patients (n=12, 10%) had all pain sites diagnosed as neuropathic 
pain. 
 Sixty-two (n=62, 50%) were nociceptive and the remaining 40% had both 
neuropathic and nociceptive pain sites  
 Most patients (n=66, 54%) reported continuous pain 
Of sites classified as neuropathic pain, words more commonly selected from 
sensory section of the MPQ were aching n=60, 53%, tender n=30, 26%, throbbing 
n=27, 24%. Aching and tender are words commonly used to describe CIBP while 
throbbing would be expected where neuropathic pain is suspected. The most 
common descriptors from the affective section were exhausting n=40, 35% and 
tiring n=36, 32% (Wilkie et al., 2001) which are both emotive and may help 
identify impact on function see Table 5. 
Table 5: Verbal descriptors for study by Wilkie et al 2001 
Pain type Key descriptors 
Neuropathic Aching (n=60, 53%)                          
Tender (n=30, 26%)             
Throbbing (n=27, 24%) 
Nociceptive Stinging (n=32, 9%)                 
Heavy (n=29, 9%)                                  
Lacerating (n=20, 6%)                                   
 
Wilkie et al (2001) described a statistically significant difference (p=<0.5) between 
descriptors chosen for neuropathic pain and those chosen for nociceptive pain. For 
example, stinging, heavy and lacerating were typically indicative of nociceptive 
pain while aching, tender, throbbing and numb were more associated with 
neuropathic pain. However, they did not find a significant relationship between 
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pain intensity and descriptors chosen. Interestingly, the authors noted that 
patients with mixed neuropathic pain and nociceptive pain experienced a higher 
pain intensity than those with only one pain type (nociceptive OR neuropathic) 
(Wilkie et al., 2001). It could be that the mixed nature of pain magnified the pain 
sensations due to the increased expression of pain.   
A noteable finding was they identified that verbal descriptors traditionally 
associated with neuropathic pain, such as burning, tingling and shooting, were not 
shown to be statistically significant as a descriptor of neuropathic pain. This could 
be due to pain being classified as nociceptive if there was no evidence to suggest 
it was neuropathic. This would further explain the larger numbers within 
nociceptive group (Wilkie et al., 2001). The small numbers of patients within the 
different pain groups limits statistical significance of results. This was a secondary 
analysis of data on lung cancer patients across 3 centres, this limits transferability 
across other cancer types, however it merited inclusion in the systematic review 
as it identified in a robust manner the verbal descriptors of patients with NCP.  
6.4.2 One-day Prevalence (Holtan and Kongsgaard, 2009) 
The second study selected for inclusion was a one-day prevalence study of 
hospitalised cancer patients at one hospital in Norway.  
 453 patients were included in the study  
 Mean pain score of 3.99 (on a 0 to 10 numerical rating scale where 0 is no 
pain and 10 is the worst pain imaginable) 
 Mean age of participants was 63.4 years  
 Key primary tumours: gastrointestinal (n=70, 15%), haematological (n=60, 
13%) or pulmonary (n=57, 12%)  
 All completed a questionnaire which collected demographic data; verbal 
descriptors translated from the short form (12 pain descriptors) MPQ and 
an adaptation of the Brief Pain Inventory (BPI) 
 97% of participants successfully described their pain using the short form 
MPQ  
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 Most common descriptors selected were; aching (n=271, 59.8%), stinging 
(n=140, 30.9%) and burning (n=93, 20.5%)  
 Patients with higher pain intensity score, piercing was found statistically 
significant (0.026, P<0.05) 
Holtan and Kongsgaard (2009) noted that stabbing showed evidence of being 
chosen more commonly by those with higher intensity pain but it was not as 
statistically significant as piercing. A further trend was that patients who scored a 
higher intensity of pain tended to choose more descriptors than those with lower 
pain intensity (Holtan and Kongsgaard, 2009). Of the 453 patients included in the 
prevalence study, 201 were found to have altered skin sensitivity. This is often a 
characteristic of someone with neuropathic pain. As this was a questionnaire-
based assessment, differentiation between pain mechanisms can be difficult to 
achieve, however the data collected showed significant results. Although the 
study did not find any clear evidence of a difference between verbal descriptors 
of neuropathic pain and verbal descriptors of nociceptive pain, they did find some 
clear similarities of descriptors chosen across a large patient population (Holtan 
and Kongsgaard, 2009). The authors of the study did not disclose information on 
disease status so conclusions could not be made regarding stage of disease and 
therefore it is difficult to characterise the patient cohort. The study was a one-
day prevalence study and convenience sample from one hospital. It had a diverse 
patient population across primary tumour type which increases transferability of 
results. It was included in this review as it met criteria for inclusion and provided 
good evidence for verbal descriptors in patients with a neuropathic cancer pain.  
6.4.3 Observational Study (Manfredi et al., 2003)  
The third study was an observational study. It differed to the studies previously 
discussed  as the focus was on describing neuropathic pain and identification of 
the cause of the pain (Manfredi et al., 2003). Clinical and demographic data were 
collected on 187 consecutive patients who attended a neuro-oncology department 
of a large cancer hospital (Manfredi et al., 2003).  All patients had been referred 
to the service for assessment and treatment of pain. All patients were assessed by 
two neurologists who aimed to gather data on the history of the pain and who 
then performed a neurological examination (Manfredi et al., 2003). The assessors 
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utilised radiological films where available and performed electrophysiological 
assessment where possible.  
 There were 187 patients included in the study 
 Mean age was 48 with equal distribution across gender (male n= 90, 48.1% 
and female n=97, 51.9 %) 
 There were 16 different sites of primary disease most common being 
sarcoma (n=22, 11.8%) and breast (n=21,11.2%) 
 157 participants had advanced (n=60, 32.0%) or metastatic (n=97, 51.8%) 
disease. The most common sites of pain were leg (n=47, 25.1%), back 
(n=34, 18.1%) or abdomen (n=29, 15.5) 
Following assessment it was found that cancer was the direct cause of pain in the 
greatest number of participants (n=145, 77.5%) (Manfredi et al., 2003). 
Neuropathic pain was identified in 103 (55%) of participants. Neuropathic pain was 
considered if patients met two of four points on a checklist. One of the checklist 
gateways was where patients had to describe their pain using the following 
descriptors; burning, electrical, cold, tingling, pins and needles or numb.  
A key finding was that of the 103 (55%) patients, with confirmed neuropathic 
cancer pain, 93 (49.7%) patients were found to have ongoing neural injury due to a 
progressing cancer. Almost half of patients would have further damage to the 
nerve as the cancer continued to progress and therefore have potential to 
experience poorly controlled pain. Manfredi et al (2003) argued that treatment in 
this group was likely to be ineffective while the injury is ongoing. Additionally, 
they described that if neural injury is not considered ‘ongoing’ that it is more 
effectively treated with adjuvant analgesia such as anticonvulsant or 
antidepressant medications. It was interesting to observe that a large proportion, 
90%, of participants with neuropathic pain were considered unlikely to receive 
benefit from adjuvant analgesia if neural injury was ongoing. This could have 
significant implications for pain assessment and management (Manfredi et al., 
2003). There were small numbers of patients included who expressed neuropathic 
pain without an ongoing neural injury, however Manfredi et al (2003) argue that 
identification of neural injury in patients with neuropathic pain will enable more 
effective treatment which is why it felt key for inclusion in this review. There was 
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inclusion of a number of different cancer types which increases translation of 
these results across cancer groups, there was also a comprehensive assessment 
performed which facilitates characterisation of patients with NCP. This study was 
included for the purposes of this review as it measured neuropathic pain using a 
predefined set of 6 verbal descriptors. Rationale for selection of these 6 
descriptors was not given and it would have been meaningful to understand 
reasons for their selection. 
6.5 Discussion 
All three of the studies discussed varied in methodology and study outcome. There 
was strong representation of patients with advanced or metastatic disease across 
studies by Wilkie et al., 2001 and Manfredi et al., 2003. While Wiklie et al 2001 
focused only on lung cancer, the others included patients with any type of primary 
cancer which affords some comparison across tumour types. 
All studies included verbal descriptors, however, Manfredi et al., 2003 included a 
pre-defined set of six descriptors and did not reference frequency of results, most 
likely as this was not the focus of their research. 
 Wilkie et al (2001) the most common descriptors were aching (n= 60, 53%), 
tender (n=30, 26%), throbbing (n=27, 24%) (Wilkie et al., 2001)  
 Holtan and Kongsgaard (2009) identified aching (n=271, 59.8%), stinging 
(n=140, 30.9%) and burning (n=93, 20.5%) as most commonly selected 
Interestingly, aching was the most common descriptor for neuropathic pain across 
the two studies, where data were available.  It also had a strong expression and 
chosen by over 50% of patients in both studies. In contrast, Manfredi et al., 2003 
did not include ‘aching’ as a descriptor for patients to select. Manfredi et al., 
2003 did not offer a rationale for choosing the 6 descriptors they included in their 
classification of neuropathic pain was however it is anticipated that this is due to 
their strong feature as descriptors of neuropathic pain as evidenced in Chapter 1. 
The descriptor burning was common to all when comparisons were made across all 
three studies, 6.4.1, 6.4.2 and 6.4.3. There was no clear consensus regarding 
definitive descriptors of neuropathic pain in cancer patients. Aching was most 
commonly selected across two studies. This descriptor is more typically associated 
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with CIBP and not traditionally used as a descriptor for neuropathic cancer pain. 
Due to the limited results for metastatic disease across multiple cancer types it 
would be useful to perform further research on patients who have completed 
assessment using verbal descriptors, for example the MPQ. It would be further 
helpful to further explore any relationship between higher pain intensity and 
verbal descriptors.  
Manfredi et al., 2003 raised a key issue regarding neural injury. It would be 
helpful to assess verbal descriptors in those with and without ongoing neural 
injury. They identified that adjuvant analgesia for patients with ongoing neural 
injury may be ineffective and it would therefore  be helpful to differentiate 
between those with ongoing injury and those without (Manfredi et al., 2003). 
Consensus across all three studies was that neuropathic pain in cancer patients is 
difficult to assess and a clearer definition of NCP is necessary to formalise 
assessment. 
6.6 Limitations 
Only three studies met inclusion criteria for inclusion in the review. There were 
763 patients across the three studies but there are few comparisons that can be 
made due to different patient populations and assessment methodology. The small 
number of studies which met criteria suggests further research is required in this 
area.  
6.7 Further reading 
The final literature search for this chapter was conducted on the 21st January 2011 
due to a break in studies. It was therefore important to perform an additional 
literature search to determine if any studies had been published since that time 
which would add further to this chapter on verbal descriptors of NCP. The same 
search criteria and terminology were used as had previously and a number of 
electronic database searches including; Medline (2010-2015), Embase (2010-2015), 
British Nursing Index (2010-2015) and the Cochrane Database of Systematic 
Reviews (2015). Keywords applied to the search were “Neuropathic pain” AND 
“Cancer” AND “Descriptors” AND “Assessment” and a combination of these. The 
new search identified 35 titles of which 11 abstracts were reviewed and 3 articles 
considered in full. The articles provided useful information about assessment tools 
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and NCP however did not add further insight to verbal descriptors of NCP and 
therefore were not included within the review chapter. The information gained 
through this additional search has been added to discussion within Chapter 2. 
6.8 Summary 
Following a comprehensive search only three studies met inclusion criteria. Aching 
was the most common verbal descriptor chosen by patients in two studies. Burning 
was frequently chosen by patients in study two and this was a descriptor which 
patients had to select in study three for inclusion. Further research is required in 
patients with metastatic disease across multiple tumour sites to assess any 
descriptors which are clearly evident of neuropathic pain. This would enhance 
clinical assessment and facilitate initiation of appropriate treatment.
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Chapter 7: Phase 2, Secondary analysis - Results CIBP 
7.1 Introduction 
This chapter considers the de novo database which utilised a dataset obtained 
from studies A and B to identify common descriptors of CIBP. As previously noted, 
data was collected on patients with clearly identifiable bone pain. The results for 
these patients are presented as follows; 
 Demographic data  
 Current treatment  
 Pain intensity McGill  
 Pain Results 
Data are initially presented in summary and are subsequently analysed in greater 
detail in reference to key aspects of the data and aims of the study. In summary 
the key aim of this study was to identify common verbal descriptors of CIBP and 
NCP. The objectives were: 
 Identify common verbal descriptors 
 Any relationship between pain intensity and verbal descriptors 
 Any relationship between verbal descriptors of CIBP and NCP 
In this chapter the study aims and objectives will be discussed in relation to CIBP 
data. 
7.1.1 Impact of living with CIBP 
This study has explored the nature and impact of CIBP on patients with advanced 
cancer. Increased morbidity and significantly reduced quality of life are highly 
associated with CIBP (Coleman, 1997, Nathan, 2005, Grond S, 1996). 
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7.2 Patient population 
Patient data were available on 146 patients with CIBP. Data from 16 patients were 
excluded because the pain was not clearly identifiable as CIBP. A further 10 were 
excluded due to incomplete or missing data. The patients ages ranged from 37 to 
88 with equal distribution across gender, (Male n=59, 49.2% and Female n=61, 
50.8%). There were 11 different types of primary cancer within the patient group. 
As expected the most common types of primary cancer were breast (n=52, 43.3%), 
prostate (n=35, 29.2%) and lung (n=14, 11.7%).  
All patients had metastatic disease with 111 (92.5%) patients having multiple bone 
metastases. Forty-nine patients (40.8%) had multiple metastases, involving other 
organs which highlights that the patient population had advanced cancer and 
would be representative of this patient group. The majority of patients were 
outpatients n=91 (75.8%) with a performance status of between zero and three 
n=119 (99.2%). Therefore, the patients included were actively living with cancer in 
the community. A large proportion, (n=68, 56.6%) of patients were receiving 
palliative radiotherapy, this would be anticipated as radiotherapy is the ‘gold 
standard’ treatment for CIBP.  Key demographic data are expressed in Table 6 and 
Table 7;   
Table 6: Patient demographics – gender and disease 
Characteristic Number (n) Percentage (%) 
Gender 
Female 61 50.8 
Male 59 49.2 
Cancer type 
Breast 52 43.3 
Prostate 35 29.2 
Lung 14 11.7 
Bladder  4 3.3 
Myeloma 4 3.3 
Large bowel 3 2.5 
Unknown 3 2.5 
Renal 2 1.7 
Bone 1 0.8 
Cervical 1 0.8 
Oesophageal 1 0.8 
Metastatic disease 
Multiple bone metastases 111 92.5 
Multiple site of metastases 49 40.8 
Single bone metastasis 9 7.5 
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Table 7: Patient demographics - ECOG and status 
7.2.1 Current treatment 
It was noted that a number of patients (n=61, 50.8%) were receiving strong opioid 
analgesia which would be expected for patients with CIBP. Patients on average 
were receiving a morphine equivalence daily dose of 76mg. Bisphosphonates are 
often used to treat patients with bone metastases, however only 27 (22.5%) of 
patients included were receiving bisphosphonates. The most common treatments 
were radiotherapy, as mentioned and hormonal treatment (n=69, 57.7%). Few 
patients receiving active treatment in the form of chemotherapy (n=20, 16.7%) 
which again indicates that patients were likely to be receiving palliative 
treatments only. The various treatments are displayed in Table 8 below; 
Table 8: Current anti-cancer treatment 
Treatment Selected by (n) Percentage (%) 
Analgesia 
Simple 33 27.5 
Weak opioid (e.g. codeine) 41 34.2 
Strong opioid (e.g. 
Morphine) 
61 50.8 
NSAID 
Yes 52 43.3 
No 48 56.7 
Current cancer treatment 
None 13 10.8 
Hormonal 69 57.5 
Chemotherapy 20 16.7 
Radiotherapy 68 56.7 
Bisphosphonates 
Yes 27 22.5 
No 93 77.5 
 
Characteristic Number (n) Percentage (%) 
ECOG performance status 
0 12 10.0 
1 49 40.8 
2 43 35.8 
3 15 12.5 
4 1 0.8 
Status   
Inpatient 91 75.8 
Outpatient 29 24.2 
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7.3 McGill Pain Questionnaire (MPQ) 
The MPQ is utilised to elicit information about the pain experience from patients 
as discussed earlier in 1.7.2. The key descriptors selected from the MPQ will be 
discussed to assess any common descriptors for CIBP. The key data is highlighted 
in Table 9. The most common descriptors selected were aching (n=60, 50%), 
gnawing (n=51, 42.5%) and throbbing (n=44, 36.7%). As highlighted in Chapter 1, 
these are descriptors which are traditionally associated with CIBP. Other 
descriptors which were commonly selected were sharp (n=39, 32.5%), tender 
(n=37, 30.8%) and shooting (n=36, 30%). These descriptors are not typically 
connected with CIBP and are familiar in textbook teaching when describing 
neuropathic cancer pain.  
Table 9: CIBP MPQ descriptor 
McGill descriptor (CIBP) Selected by (n) Percentage (%) 
Aching 60 50 
Gnawing 51 42.5 
Throbbing 44 36.7 
Sharp 39 32.5 
Tender 37 30.8 
Shooting 36 30.0 
 
7.4 Summary 
Patients with CIBP were found more commonly to be outpatients with a moderate 
performance status. Patients with breast, prostate and lung cancer were more 
affected by CIBP than other tumour types. It was noted that a number of patients 
with CIBP received strong opioid medication with an average daily dose of 76mg of 
morphine. Patients with CIBP had a variety of recent or ongoing treatments 
including hormonal therapy, bisphosphonates and chemotherapy. One of the most 
common treatments was radiotherapy which is a treatment often utilised to treat 
painful bone metastasise which cause CIBP. The most common verbal descriptors 
associated with CIBP were aching (n=60, 50%), gnawing (n=51, 42.5%) and 
throbbing (n=44, 36.7%). This chapter has characterised the patient cohort with 
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CIBP and highlighted key verbal descriptors associated with CIBP. The following 
chapter aims to present the same information for patients with NCP and explore 
verbal descriptors of NCP. 
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Chapter 8: Phase 2, Secondary analysis - Results NCP 
8.1 Introduction 
This chapter considers data obtained from studies A and C as, highlighted in 
Chapter 4, to identify common descriptors of NCP. In studies A and C, data were 
collected from patients with clearly identifiable neuropathic pain. The results for 
these patients are presented as follows; 
 Demographic data  
 Current treatment  
 Pain intensity McGill  
 Pain Results 
The data are presented in summary but are subsequently analysed in greater 
detail with reference to key aspects of the data and study aims. On statistical 
advice it was not useful to perform Confidence Intervals (CIs) on the data as the 
raw data numbers were too small for meaningful statistical analysis.  As previously 
stated the key aim of this study was to identify common verbal descriptors of CIBP 
and NCP. The objectives were: 
 Identify common verbal descriptors 
 Any relationship between pain intensity and descriptors used 
 Any relationship between verbal descriptors of CIBP and NCP 
In this chapter the study aims and objectives will be discussed in relation to NCP 
data. 
The impact of living with cancer, as discussed in Chapter 1, NCP occurs in 
approximately 40% of patients with cancer and can often indicate disease 
progression (Bruera, 2003). The damage to nerves by cancer or cancer treatment 
can affect patient quality of life and is potentially debilitating. The pain can be 
expressed as a mixture of background pain with spontaneous or triggered 
exacerbations.  
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8.2 Patient population 
Patient data were available on 91 patients with NCP. A number (n=30) were 
excluded due to incomplete or missing data, some key data are highlighted in 
Table 10 and Table 11. 
Table 10: Patient demographics – Gender and disease 
Characteristic Selected by (n) Percentage (%) 
Gender 
Female 36 59.0 
Male 25 41.0 
Type of cancer 
Breast  21 34.4 
Lung 9 14.8 
Other 17 27.9 
Myeloma 4 6.6 
Prostate 3 4.9 
Renal 2 3.3 
Number of metastatic sites   
0 17 27.4 
1 24 38.7 
2 11 17.7 
3 8 12.9 
4 1 1.6 
Common metastatic sites 
Multiple bone metastases 25 41.0 
Lung 15 24.6 
Liver 12 19.7 
Lymph nodes 7 11.5 
 
The age of patients ranged from 38 years to 83 years, the majority of which were 
female, Female n=36 (59.0%) and Male n=25 (41.0%). There were 22 different 
types of primary cancer within the patient group. There was wide distribution 
across primary tumour type, the most common types of primary cancer were 
breast (n=21, 34.4%) and lung (n=9, 14.8%). A large percentage of patients had one 
site of metastatic disease, n=24, 38.7%, however over 25% of patients had no 
metastatic disease (n=17, 27.4%). It should be noted that while these patients did 
not have metastatic cancer, they would have had loco-regionally advanced disease 
for which there was no cure.  
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Table 11: Patient demographics - ECOG and status 
Performance status (ECOG) 
0 32 52.5 
1 2 3.3 
2 18 29.5 
3 8 13.1 
4 1 1.6 
Status 
Outpatient  40 65.6 
Inpatient 18 29.5 
Analgesia 
Simple 12 19.7 
Weak opioid 3 4.9 
Strong Opioid 45 73.8 
 
The majority of patients were outpatients, n=40, 65.6% with a performance status 
either zero (n=32, 52.5%) or two (n=18, 29.5%) and over 70% (n=45, 73.8%) of 
patients were receiving a strong opioid with a morphine equivalence on average 
on 155.6mg. 
8.3 McGill Pain Questionnaire (MPQ) 
As discussed, the MPQ can elicit information about the pain experience from 
patients as discussed earlier in 1.7.2. The most common descriptors selected from 
the MPQ are highlighted to assess any common descriptors for NCP. The key data 
is highlighted in Table 12. The most common descriptors selected were; tender 
(n=34, 55.7%), aching (n=31, 50.8%), and sharp (n=28, 45.9%). Other descriptors 
which were commonly selected were throbbing (n=27, 44.3%) shooting (n=24, 
39.3%), stabbing (n=24, 39.3%) and hot (n=23, 37.7%).  
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Table 12: NCP McGill descriptors 
McGill descriptor (NCP) Selected by (n) Percentage (%) 
Tender 34 55.7 
Aching 31 50.8 
Sharp 28 45.9 
Throbbing 27 44.3 
Shooting 24 39.3 
Stabbing 24 39.3 
 
The two most commonly selected verbal descriptors by those with NCP, tender 
and aching, were chosen by over 50% of the patient group indicating these are 
important descriptors of NCP. These two descriptors are more commonly 
associated in the literature with CIBP as described in Chapter 5.  
8.4 Summary 
Patients with NCP were found more commonly to be outpatients with a good 
performance status which suggests they continue to maintain a level of 
independence. Patients with breast cancer were more affected by NCP than other 
tumour types however there was wider distribution across tumour type than those 
in the CIBP patient cohort. It was noted that a number of patients with NCP 
received strong opioid medication with an average daily dose of 155.6 mg of 
morphine. The most common verbal descriptors associated with NCP were tender 
(n=34, 55.7%), aching (n=31, 50.8%) and sharp (n=28, 45.9%). This chapter has 
characterised the patient cohort with NCP and highlighted key verbal descriptors 
associated with NCP. The following chapter will compare and further discuss the 
patient cohorts with CIBP and NCP. 
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Chapter 9: Phase 2 – Secondary objectives 
9.1 Introduction  
Results presented in Chapters 7 and 8 considered the characterisation of patients 
with CIBP and NCP through secondary analysis. This understanding is pivotal in 
acknowledging the impact of pain for patients. Meaningful assessment can be 
developed through a greater understanding of the impact of pain. It is important 
to understand the unique characteristics of pain but also to acknowledge any 
similarities in pain description. Such understanding will help identify where 
current pain assessments are limited and facilitate identification of how 
assessment tools could be further developed. The primary objective was to 
compare verbal descriptors of CIBP and NCP. However, this chapter will consider 
relationships in the following areas: 
 Gender and worst pain score 
 Pain scores across cancer type 
 Patients performance status  
 Comparative analgesia and treatment  
9.2 Gender and worst pain score 
The data were considered to determine if any relationship existed between 
gender and worst pain score. Gender was the terminology utilised in literature 
around this topic and as such is adopted in this thesis (Deandrea, 2014). This was 
to identify if patients could be characterised by gender; for example, would one 
group experience pain at heightened severity compared to the opposite gender? A 
variation in pain experience by gender could be a key consideration in pain 
assessment and would allow for development of gender specific assessment. The 
worst pain more commonly selected across CIBP and NCP groups is displayed in 
Table 13 and it demonstrates no difference in pain scores between genders.  
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Table 13 Gender and worst pain score 
Gender Worst pain score (CIBP) Worst pain score (NCP) 
Male  8/10 (n=12, 20.3%) 8/10 (n=8, 32%) 
Female 8/10 (n=10, 16.7%) 10/10 (n=7, 19.4%) 
 
There was consensus in worst pain scores of those in the CIBP cohort where worst 
pain score of 8/10, (on a 0-10 NRS), was selected by both male and female 
participants. Interestingly, no greater pain expression was identified between 
gender groups. The male cohort of patients with NCP scored worst pain most 
commonly as 8/10 (n=8, 32%) while the women chose 10/10 for worst pain more 
commonly (n=7, 19.4%). It should be noted that due to the small numbers there is 
not a strong relationship between worst pain score and gender.  Due to the small 
numbers considered, further exploration in a larger group is required to clearly 
identify any difference in pain reporting measures between genders.  
While considering the impact of gender on pain reporting, it was found that 
irrespective of pain origin, there was similar distribution between male and 
female participants. Table 14 highlights that both genders were represented in 
similar numbers across the pain groups. 
Table 14: CIBP vs. NCP key demographics 
  
Gender 
CIBP (n=120) NCP (n= 61) 
n % n % 
Female 61 50.8 36 59 
Male 59 49.2 25 41 
 
The data demonstrates no difference between gender and prevalence of either 
CIBP or NCP nor a gender bias for reporting CIBP or NCP. This means there is not a 
strong case to recommend a gender specific assessment tool. Gender is not a 
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strong characteristic in pain. However, an opportunity to explore a larger sample 
size would be useful.  
9.3 Pain scores across cancer types 
While considering key characteristics in pain assessment in parallel with verbal 
descriptors, the data were assessed for any relationship between type of primary 
cancer and the incidence of CIBP or NCP. The results displayed in Table 15 were 
used to identify if a cancer type increased risk of CIBP or NCP.  
Table 15: Cancer type 
Type of Cancer CIBP NCP 
 n %  n  %  
      Breast 52 43.3 21 34.4 
      Prostate 35 29.2 3 4.9 
      Lung 14 11.7 9 14.8 
      Large Bowel 3 2.5 5 8.2 
      Myeloma 4 3.3 4 6.6 
      Renal 2 1.7 2 3.3 
      Other 10 8.3 17 27.9 
 
It was evident that breast cancer was most common across both CIBP and NCP 
groups, over 43% or CIBP patients and over 34% of NCP patients were breast cancer 
patients. As described in Chapter one, cancers which commonly metastasize to 
bone are breast, lung and prostate and therefore it is reasonable that over 80% of 
those with CIBP expressed these as the primary cancer type. Patients with NCP are 
more difficult to predict as it is not strongly associated with a specific cancer 
type. This is shown in Table 15 as there was greater distribution across cancer 
type. As previously described in Chapter 1, NCP can be caused by any tumour and 
by a variety of treatments; therefore, it could be possible for patients with many 
different tumours to experience NCP.  
It is important to note that data presented within Table 16 relates to disease 
progression, it refers to how advanced the cancer was at the time of data 
collection. Patients included for the purposes of the secondary analysis could have 
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had varying degrees of disease progression but it is important to identify that all 
patients included had to have progressive disease by definition, for which there 
was no possible cure.  
Table 16: Disease progression 
Type of distant 
disease 
CIBP NCP 
n % n % 
Multiple bone 111 92.5 25 41 
Multiple mets 49 40.8 42 67.7 
Singe bone 9 7.5 2 3.3 
 
Patients with CIBP, in this dataset have, by definition, metastatic bone disease; 
CIBP would not exist without skeletal disease. Patients could have a single bone 
metastasis or multiple cancer deposits throughout the skeleton. Those with bone 
metastases could also have other sites of distant disease and this information is 
included as it helps describe the patient population and highlight the burden of 
disease.  
It is clear that those with CIBP had progressive disease. Almost 93% had multiple 
sites of bone metastases with 40% of patients having had multiple sites of distant 
disease. Those with NCP also had advanced disease with almost 68% having had 
multiple sites of distant disease. The data did not highlight any trend between 
type of primary cancer and whether a patient had CIBP or NCP but it was evident 
that patients with CIBP and NCP had progressive cancer. 
While the majority of patients with NCP had progressive disease, almost 30% of 
patients did not have distant sites of cancer. This is noteworthy as those with loco 
regionally advanced cancer could also experience significant pain as compared to 
those with progressive, distant disease. It is evident for both CIBP and NCP, 
patients with a primary breast cancer are at greater risk of developing CIBP 
and/or NCP due the risk of metastatic bone disease and locality of a primary 
breast tumour to large nerve pathways in the axilla as highlighted in 1.6.  
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Patients with CIBP have metastatic bone disease which can serve as a predictor of 
pain. It is more difficult to predict those at risk of NCP which in turn increases 
difficulty in assessment of NCP. This is an indication that further research is 
required to test for any risk factors in development of NCP across a larger patient 
population.  
9.4 Patient performance status  
Further characterisation was achieved through assessment of performance status 
as defined by ECOG and discussed earlier in Chapter 7. This section will compare 
how functionally fit the patients were at the time of assessment. It was examined 
if those with CIBP or NCP are considered less well or experience a greater loss of 
functionality compared to those in the other cohort. The key findings are shown in 
Table 17. 
Table 17: Patient function 
Performance status 
(ECOG)** 
CIBP (n=120) NCP (n=61) 
n % n % 
Decreasing 
function 
 
0 12 10 32 52.5 
1 49 40.8 2 3.3 
2 43 35.8 18 29.5 
3 15 12.5 8 13.1 
4 1 0.8 1 1.6 
Inpatient/outpatient 
Status 
  
      Outpatient 91 75.8 40 65.6 
      Inpatient 29 24.2 18 29.5 
** Eastern Cooperative Oncology Group (ECOG) 
 
Table 17 shows that patients with CIBP exhibited poorer function than those in the 
NCP group. Using the Eastern Cooperative Oncology Group (ECOG) performance 
status (PS) scale, over 75% of patients with CIBP were either performance status 
one (n=49, 40.8%) or two (n=43, 35.8%). This indicates that these patients, at 
best, could perform all self-care and, at worst, be unable to complete any light 
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work either at home or at the office.  It’s worth noting that while the majority of 
CIBP patients were expressed within the mid-section of the ECOG, as many as 76% 
(n=91,75.8%) were outpatients at time of data collection.  
The group with NCP were more functionally fit than the CIBP counterparts. Over 
50% (n=32, 52.5) of patients with NCP had a performance status of zero. Patients 
with an ECOG PS of zero are described as fully active and capable of performing 
all pre-disease activities without restriction. There were a considerable number, 
n=18 (29.5%) of those with NCP who were assessed as ECOG PS of 2. Therefore, 
patients were either able to continue with normal daily living activities or quite 
restricted in daily life. Within the NCP cohort, n=18, 29.5% were inpatients and 
n=40, 65.6% remained as outpatients at time of inclusion Patients with CIBP 
expressed a poorer performance status than those with CIBP.  
The majority of patients with pain, irrespective of mechanism, were supported in 
the community. It is not known how much support these patients received from 
the community teams, through symptom management or home adaption to 
facilitate and promote independence. This is particularly relevant for those with 
CIBP as these patients tended to have a lower ECOG performance status but 75% 
remained as outpatients and this would have implications for community support. 
These findings support further objective research to explore the experience of 
patients with pain and varying performance status as inpatients and outpatients. A 
qualitative study could explore any emerging themes on what is important to 
patients with pain such as CIBP and NCP. Particularly to identify what is required 
to support patients with CIBP and NCP effectively within the community. To 
understand the needs of this patient group a prospective study or audit would be 
useful to assess services utilised, for example community MacMillan nurses, 
occupational therapy, hospice.  
9.5 Comparative analgesia and treatment of CIBP vs. NCP 
It has been identified that patients with CIBP and NCP often require multiple 
analgesia and Chapter 8 explores the requirements of patients. Theme four 
compares the use of opioid and adjuvant analgesia across the pain groups to assess 
any difference in doses required or type of analgesia utilised. This information will 
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assist in understanding if CIBP or NCP appears more challenging to manage. Table 
18 displays strong opioids analgesia utilised by patients. 
Table 18: Strong opioids 
                                        CIBP (n= 120) NCP (n= 61) 
n  % n  % 
Strong opioid (e.g. 
Morphine) 
61 50.8 45 73.8 
 
In the NCP cohort, almost 74% of all patients were taking a strong opioid 
compared to almost 51% of those with CIBP. The high frequency of those on strong 
analgesia reflects high levels of pain experienced by the patients included in 
analysis.  
There is a higher than expected degree of difference between those prescribed 
strong opioids with CIBP and those with NCP. It was highlighted in Chapter 1 that 
both CIBP and NCP were complex types of pain and therefore it was considered 
that both patients groups might have similar opioid requirements (Shaiova, 2006) 
but within this patient cohort there is a marked difference.  
As evidenced below in Table 19, patients with CIBP had similar distribution 
between simple analgesia and weak opioids while those in the NCP group 
appeared to either have simple analgesia or strong opioids. This might suggest 
there were very few who found adequate pain relief on simple analgesia. 
Table 19: Simple and Weak analgesia 
 CIBP (n= 120) NCP (n= 61) 
n % n % 
Simple 33 27.5 12 19.7 
Weak opioid (e.g. 
codeine) 
41 34.2 3 4.9 
 
Table 20 displays anti-cancer treatment the patients were receiving at the time 
they were assessed. This information enhances understanding of the patient 
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cohort as it allows comparison of the variety of treatments given to the different 
pain groups to identify any similarities or differences. 
Table 20: Comparative anti-cancer treatment 
Anti-cancer treatment  CIBP NCP 
 
n % n % 
Hormone (e.g. breast, prostate) 69 57 11 18 
Radiotherapy (e.g bone metastases) 68 56.7 4 6.6 
Bisphosphonates (e.g. bone 
metastases) 27 22.5 0 0 
Chemotherapy (control disease 
progression) 20 16.7 10 16.4 
No treatment 13 10.8 33 54.1 
NB All treatments given with palliative intent & some patients on combination treatments 
 
Unsurprisingly, the patients with CIBP were receiving hormone treatment. This is 
because the most common cancer types were breast and prostate cancers, both 
often employ hormonal therapies to manage disease. As identified in Chapter 1, 
patients are offered palliative radiotherapy for painful bone metastases; 
therefore, it is entirely not unexpected that almost 57% of those with CIBP had 
received palliative radiotherapy, as they had bone metastases.  
Patients within the NCP group received very little anti-cancer treatment and over 
50% of NCP patients were not receiving any anti-cancer treatment. This could be 
explained by the greater diversity in primary tumour type as highlighted Table 14. 
Patients would be unlikely to receive bisphosphonates if they did not have bone 
metastases however it was observed that 44.3% had some metastatic bone 
disease. It may have been inappropriate to offer chemotherapy or radiotherapy to 
manage the disease with the types of cancer or expected results.  
Patients with CIBP commonly reported radiotherapy and bisphosphonates as anti-
cancer treatments. Radiotherapy and bisphosphonates could be employed to 
specifically treat CIBP which could explain the disparity in current treatments 
between CIBP and NCP. The anti-cancer treatment could be utilised to treat the 
CIBP and therefore, while they can be used to treat NCP, you would expect to see 
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less prevalence in the NCP cohort as these treatments are not commonly 
employed.  
Further research is therefore recommended to explore further treatment options 
for patients with NCP. While the data within the secondary analysis are limited it 
merits further exploration of the topic. With less treatment options available for 
patients with NCP compared to those with CIBP, it would be beneficial to explore 
the role of poly-pharmacy and early detection of pain to achieve meaningful 
analgesia for patients. 
9.6 Summary 
This chapter has shown that NCP is harder to predict, more difficult to treat 
effectively and has fewer treatment options available. It has further shown that 
while patients with CIBP and NCP express similarities in pain severity, patients 
with NCP often require more strong opioids while those with CIBP express poorer 
performance status. This chapter has identified more research is required to fully 
explore these four themes across a larger group of patients with CIBP, NCP and 
mixed pain. Only then can definitive assessment be developed. 
A key aspect of assessment of CIBP and NCP has been considered as the verbal 
descriptors of CIBP and NCP. The following chapter will demonstrate the most 
common verbal descriptors of CIBP and NCP and discuss the implications of these 
on pain assessment. 
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Chapter 10: Key comparisons and Common Verbal descriptors 
10.1 Introduction 
The previous chapter explored four characteristics of patients with CIBP and NCP. 
These have afforded an insight to severity, impact and treatment of their pain. 
Although the primary objective of this project was to identify verbal descriptors of 
CIBP and NCP, it was also hoped to gain a better understanding about the two 
types of pain and the other features of patients who experience CIBP and NCP.  
This chapter summarises the key comparisons between the two groups with a 
focus on the common verbal descriptors selected by patients. Table 21 presents 
the characteristics considered as important for comparison.  
 
Table 21: Analgesia and ECOG performance status 
 
From personal clinical experience and from literature in Chapter 1, it was 
expected that patients with CIBP and NCP would experience high levels of pain 
and perhaps be on multiple analgesia. To achieve effective pain management for 
patients it is important to have an appreciation of the mechanism of pain but 
moreover the impact of pain on the patient.  
From Table 21, it is apparent that patients were five times more likely to be on 
adjuvant analgesia if they had NCP compared to those with CIBP (70.5% compared 
to 13.9%). This difference is remarkable considering the similar challenges in 
managing both types of pain. While it is known that adjuvant analgesia such as 
 
NSAID Adjuvant analgesia ECOG 
CIBP n=52,43.3% n=17,13.9% 2 
NCP n=22,36.1% n=43,70.5% 2 
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antidepressants and anticonvulsants are often utilised to treat NCP, it would have 
been anticipated for the CIBP cohort to have expressed a higher use of adjuvant 
analgesia than 13.9%. This was certainly expected to be higher than 13.9% because 
often this patient group experience inadequate analgesia with opioids alone 
(Nabal, 2012). Table 22 offers further comparative information and each will be 
discussed below. 
Table 22: Opioids, pain and verbal descriptors 
 
 
10.2 Morphine Equivalence Daily Dose 
Another area which offered interesting comparison was the opioid morphine 
equivalence daily dose (MEDD).  Patients with NCP were found to have a morphine 
equivalence daily dose of twice that of the patients in the CIBP cohort. This was 
higher than expected as opioids are known to be utilised in CIBP.  
Sustained release opioids are utilised for background pain and immediate release 
opioid preparations are used in CIBP to manage incident pain and breakthrough 
pain as illustrated in Chapter 1. Opioid doses are escalated in parallel with pain 
severity until satisfactory management or unacceptable adverse effects, it would 
therefore have been anticipated that the CIBP cohort would have had a higher 
MEDD than those in the NCP group. The use of opioids to treat NCP has been 
documented as having limited effect. Opioids are usually used in combination with 
other analgesia which was discussed in Chapter 1. Moreover, for patients with NCP 
there are a number of adjuvant analgesia which are known to offer benefit and 
that have been used to treat NCP such as antidepressants, NSAIDs and 
 
MEDD 
(Opioids) 
Worst pain (VAS 
≥ 5/10) 
Average pain 
(VAS ≥ 5/10) 
Most common 
descriptors 
CIBP 76mg N=93,79.5% N=48,43.2% Aching, Gnawing, 
Throbbing 
NCP 155.6mg N=55,90.2% N=39,63.9% Aching, Tender, 
Sharp 
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anticonvulsants as highlighted in Chapter 1. It could be postulated that patients 
with CIBP have access to a wider range of treatments compared to those with NCP 
which has potential to influence the opioid doses required. 
The higher incidence of adjuvant use and the higher MEDD in the NCP would 
suggest those with NCP have worse pain than those in the CIBP group. It was 
further observed that patients with NCP more commonly scored a worst pain score 
of ≥ 5/10 across than in the CIBP cohort. Patients with NCP were also found to be 
more likely to have an average pain score of ≥ 5/10 than those with CIBP.  
A difference in average pain could be explained by characterisation of CIBP and 
pain existing as a lower level background pain with episodes of worsening 
breakthrough pain. As described in Chapter 1, those with NCP may have 
experienced prolonged periods of heightened pain therefore expressing a higher 
average pain than those with CIBP.  
10.3 Common verbal descriptors 
While CIBP and NCP were expected to be more similar in severity and treatment 
the verbal descriptors were anticipated to be quite different. We know from the 
literature in Chapters 1, 5 and 6 that there are verbal descriptors associated with 
CIBP such as aching and dull and for NCP sharp and shooting.  
From the data extracted for the secondary analysis, a prominent descriptor for 
CIBP and NCP was aching. Aching is traditionally associated with CIBP and not 
typically considered as an identifier of NCP. Throbbing was commonly selected in 
the CIBP cohort although this is traditionally thought to be an identifier of NCP. 
Tender is known to be linked to those with a painful bone metastasis however this 
was found as popular within the NCP group.  
Within medicine, research is always being conducted. Research helps to drive 
change in healthcare through improved assessments, technology, tests, and 
treatments, while hopefully improving the patient experience.  
Pain has been assessed by numerical scales, colourful visual analogue scales and 
verbal descriptors; however, we still have more to learn as a proportion of 
patients fail to achieve meaningful analgesia. The degree of meaningful analgesia 
will vary between each individual and it would be helpful for the patient and care 
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giver to have a pain assessment tool which facilitates diagnosis of pain and 
supports prompt initiation of appropriate treatment. Consideration of the 
emotional touchpoints along with validated pain assessment tools may offer a 
more comprehensive pain assessment.   
10.4 Verbal descriptor similarities 
Previous sections have considered the difference and similarities of characteristics 
such as pain intensity and analgesia. The following section focuses on any 
similarities between the verbal descriptors selected by participants. As health 
care providers we ask patients to rate their pain, describe their pain, and measure 
their pain. The aim of this MSc was to gain understanding of the verbal descriptors 
of CIBP and NCP to identify any difference between these two difficult and 
debilitating pain experiences. The desire is to characterise these two pain 
conditions and identify gaps in knowledge. Only through understanding of the 
patient experience can we determine if current pain assessments accurate 
capture and diagnose pain mechanisms. Once pain mechanism is accurately 
determined appropriate treatment can be commenced. 
It is shown below in Table 23, the six verbal descriptors most commonly selected 
by patients with CIBP and NCP, this is further expressed in Figure 11.  
Table 23: Common Verbal Descriptors 
McGill descriptor (NCP) CIBP NCP 
Aching n=60 (50.0%) n= 31 (50.8%) 
Gnawing n=51 (42.5%)  
Sharp n=39 (32.5%) n= 28 (45.9%) 
Shooting n=36 (30.0%) n=24 (39.3%) 
Stabbing  n= 24 (39.3%) 
Tender n=37 (30.8%) n=34 (55.7%) 
Throbbing n=44 (36.7%) n= 27 (44.3%) 
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For patients with CIBP, the most common is aching and for NCP, Tender was most 
commonly selected. The only unique descriptor to CIBP was gnawing and 
within the NCP cohort, stabbing was the only descriptor across the top six 
most common which was unique to NCP. The six most common descriptors 
feature several similarities across CIBP and NCP which are presented further in 
Figure 11. 
Figure 11 - Crossover descriptors 
 
 
Figure 11 shows quite clearly that of most common descriptors for CIBP and NCP, 
five out of the six selected are the same for CIBP and NCP. This indicates that 
patients may describe a similar pain experience irrespective of mechanism of pain 
and these descriptors are not discriminating. Therefore, differentiating between 
CIBP and NCP using verbal descriptors would be inaccurate using current pain 
assessment tools which utilise such verbal descriptors to differentiate between 
CIBP and NCP. Descriptors currently used to define CIBP and NCP may be 
inaccurate and result in inadequate analgesia. It is therefore required that 
accurate assessment moves beyond the common toward the unique. 
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10.5 Summary 
This chapter has shown a crossover of verbal descriptors between CIBP and NCP. 
Of the most commonly selected descriptors from the dataset, gnawing and 
stabbing were identified as more definitive of CIBP or NCP. 
Due to the similarities in verbal descriptors across both pain groups, more 
research is required to develop an assessment tool which can discriminate 
between CIBP and NCP. An assessment tool is required to facilitate communication 
of their experience of pain.  
A large prospective study to explore the themes identified within this chapter is 
recommended to investigate which verbal descriptors differentiate between CIBP 
and NCP. Using the verbal descriptors identified in this chapter, a prospective 
study could map of priorities for pain assessment. It would further allow 
exploration of verbal descriptors noted to be important within this chapter such as 
tender, aching and sharp. The following chapter will consider conclusions from 
this secondary analysis and explore recommendations for future research and 
practice. 
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Chapter 11: Conclusions and Recommendations 
11.1 Conclusions 
The secondary analysis utilised within this MSc has permitted exploration of verbal 
descriptors of CIBP and NCP in pre-existing datasets. While secondary analysis has 
proven challenging, it has afforded some insight into the patient pain experience. 
This chapter will offer conclusions on the study objectives drawn from the data 
analysed and will make recommendations for future practice and research. 
11.2 Overall objective  
Identify the verbal descriptors of CIBP and NCP.  
Conclusion - Patients with CIBP selected aching as the most common verbal 
descriptor while tender was most commonly selected for NCP. 
11.3 Secondary objectives 
1. Identify verbal descriptors more commonly associated with CIBP by 
conducting a systematic review of the existing literature.  
Conclusion – CIBP is traditionally associated with dull or aching but also 
noted to be described within literature as annoying or gnawing. 
2. Identify verbal descriptors more commonly associated with NCP by 
conducting a systematic review of the existing literature.  
Conclusion – NCP is described as aching and burning within literature. 
3. To perform an examination of the relationship between pain intensity and 
gender, cancer type, performance status and analgesia. 
Conclusion - The data demonstrates no difference between gender and 
prevalence or reporting of either CIBP or NCP. Metastatic bone disease can 
serve as a predictor of CIBP but is more difficult to predict those at risk of 
NCP. Patients with CIBP had a lower ECOG performance status than those 
with NCP. Patients with NCP were found to have twice the daily opioid 
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requirements of those with CIBP, they were further noted have greater 
opioid requirements.  
4. To examine any common or unique verbal descriptors of CIBP and 
NCP. 
Conclusion – Gnawing was found more common in patients with CIBP, 
while stabbing was found more common in NCP. A crossover of 
verbal descriptors was identified therefore many common verbal 
descriptors of pain could not be used to distinguish between CIBP 
and NCP. 
11.4 Recommendations 
Education 
 Education of nurses and patients about communication of pain is 
recommended.  
 Facilitating patients to communicate their pain effectively to achieve their 
goals to maintain quality of life.  
Research 
 Further research is required to assess the role of verbal descriptors in pain 
assessment. Particularly any role for use of verbal descriptors to diagnose 
pain origin.  
Practice   
 Person-centred pain assessment is recommended.  
 Tools to support clinical assessment are useful for patients and healthcare 
providers to communicate and encourage discussion about pain. 
11.5 Summary 
In summary, verbal descriptors of CIBP and NCP have been shown to express 
similarities when using pain assessments tools which employ verbal descriptors. 
Further research is merited to explore both the common descriptors and also 
those unique to CIBP or NCP. Through this MSc it has been identified that a 
comprehensive assessment tool with task-orientated goal setting at its core would 
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be of benefit to both patients and nurses. This would facilitate accurate pain 
assessment and pain management where person-centred quality of life is the 
ultimate goal. The final chapter will offer reflection on the experience of 
undertaking a secondary analysis and consider any skills learned which would be 
taken forward to the next project. 
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Chapter 12: Reflection – Lessons learned 
12.1 Introduction 
The focus of this project was derived from experience in palliative care clinical 
trials. Exposure to this patient group enabled access to the datasets used for this 
MSc. Similar questionnaires employed different formats among different patient 
cohorts where pain was the common denominator. Discussions with a colleague 
surrounding the importance placed on verbal descriptors in pain assessment led to 
the development of this thesis. Throughout the process, from data extraction 
through to analysis and discussion, I have gained many new research skills and 
gained a greater understanding of the cancer journey and pain assessment. This 
chapter will discuss this journey and those new skills. It will further identify what 
could have been performed differently and what I would take forward to my next 
project. 
12.2 Systematic review 
The process of conducting systematic review of the literature was challenging but 
I gained new skills in critical appraisal. I gained confidence to argue with an 
experienced researcher on articles I felt merited inclusion in review. Using an 
adaptation of SIGN 50 checklist enabled me to focus on the key components of 
each article and apply the same methodical, critical approach. I further learned to 
have conviction in my review of research articles, to assess methodology and 
make comment on rigour. Through describing my methodology, I also learned of 
other techniques such as PICO which can support systematic review of the 
literature and this knowledge I will take onto future projects. 
12.3 Database management 
Creation of a de novo database through data extraction across three studies was 
challenging. Learning to assess appropriate data for inclusion was aided by an 
experienced statistician who reviewed the data entered into the de novo database. 
The statistician further assisted by reviewing the database design and screening 
appropriate exploratory outcome measures. Through the process I developed a 
high threshold for data inclusion in the de novo database as the data had to be 
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sufficiently complete to allow comparison. I identified challenges in comparing 
data across studies and the expectations of data to answer outcomes. I found it 
important to set clearly defined aims and goals while also managing sample size 
expectation. I firmly believe these key areas of will help with designing future 
research and also for advising others considering a secondary data analysis.  
While I have always known the importance of complete data I have gained a 
greater understanding of the implications of missing data on potential for 
secondary analysis and have applied this knowledge in my work as a research 
nurse. 
12.4 Resubmission 
Following VIVA examination, and consideration of the comments, I was afforded 
an opportunity to revisit my thesis and revise the work undertaken. Revision of 
this project has taught me to ensure I make detailed notes to enable the work to 
be reproduced and to understand how I made assessments or study decisions. I 
learned that I must be explicit in my explanation of my research process and to 
signpost for the reader how I achieved study outcomes.  
12.5 Verbal descriptors 
I previously considered CIBP and NCP as distinct and separate pain experiences. 
Through this MSc I have learned more about verbal descriptors and the crossover 
between CIBP and NCP. I have a greater understanding of the impact undertreated 
pain on the patient and the importance of comprehensive pain assessment. This 
has affected my discussions with patients when assessing pain where I now rely on 
patient description before prompting with my preconceived descriptors. I have 
further disseminated my experience with colleagues and opened discussions and 
reflection around pain and pain assessment. 
12.6 Limitations of the study 
Extracting data from existing datasets offered challenges due to incomplete data 
and difficulty in direct comparison across three datasets. The secondary nature of 
this study meant the results could only be interpreted against the anonymised 
patient sample available and therefore any generalisations are limited. Careful 
selection of data sets is imperative to maximise comparability to ultimately 
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improve patient care. Using reflection throughout the process of developing a de 
novo database allowed any learning from the CIBP data extraction to be 
transferred into extraction of NCP data. As a part-time student, feasibility was key 
to the success of the research however; having reflected on the processes a key 
contribution to the patient care has been identified. 
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Appendix 1: Descriptors of CIBP and NCP 
Database Coding Version 3 
Reason for attendance 
T Treatment of bone disease or its 
complication 
O Other 
 
Primary cancer site 
Code Site 
1 Breast 
2 Lung 
3 Prostate 
4 Renal 
5 Large Bowel 
6 Anal 
7 Pancreatic 
8 Stomach 
9 Head and Neck 
10 Brain 
11 Thyroid 
12 Myeloma 
13 Lymphoma 
14 Ovarian 
15 Mesothelioma 
16 Cervical 
17 Oesophageal 
18 Bone 
19 Bladder 
20 Uterine 
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21 Unknown 
22 Plasmacytoma 
23 Sarcoma 
24 Carcinoid 
25  Chronic Myeloid Leukaemia 
26 Squamous cell carcinoma 
27 Adenoid cystic carcinoma 
28 Rectum 
29 Waldenstrom’s macroglobulinaemia 
 
Disease Status 
N No active disease 
LD Local disease 
LR Loco-regionally advanced 
M Metastatic disease 
 
Metastatic sites 
B Bone unspecified 
BS Bone Single 
BM Bone Multiple 
LI Liver 
LU Lung 
BR Brain 
AD Adrenal 
PE Peritoneal 
OV Ovarian 
PL Pleural 
LN Lymph Node 
RE Renal 
SK Skin 
LM Leptomeningeal 
MD Mediastinum 
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VA Vaginal 
SC Subcutaneous 
CU Cutaneous 
AB Abdomen 
 
Current anti-cancer treatment 
N None 
H Hormonal 
C Chemotherapy 
RT Radiotherapy 
RI Radioisotopes 
S Surgery 
BI Biphosphonates 
MA Monoclonal Antibody 
 
Previous treatment to Pain site 
RT Radiotherapy 
C Chemotherapy 
S Surgical 
RA Regional anaesthesia 
H Hormonal 
RI Radioisotope 
BI Biphosphonates 
 
Opioids 
1 Nil 
2 MST 
3 Oxycontin 
4 Hydromorphone SR 
5 Severedol 
6 Oramorph 
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7 Oxynorm 
8 Hydromorphone IR 
9 Diamorphine 
10 Fentanyl 
11 Zomorph 
12 Alfentanyl 
13 Methadone 
14 Unspecified strong opioid 
 
Non-Opioids 
1 Ibuprofen 
2 Voltarol 
3 Naproxen 
4 Paracetamol 
5 Co-Codamol 8/500 
6 Co-Codamol 30/500 
7 Codydramol 
8 Dihyrdrocodeine 
9 Rofecoxib 
10 None 
11 Celebrex 
12 Homeopathic remedies 
13 Amitriptlline 
14 Lignocaine patch 
15 Gabapentin 
16 Coproxamol 
17 Aspirin 
18 Flurbiprofen 
19 Imipramine 
20 Arthrotec 
21 Dexamethasone 
22 Fluoxetine 
23 Venlafaxine 
  109 
24 Unspecified NSAID 
25 Unspecified anticonvulsant 
26 Unspecified antidepressant 
27 Unspecified other 
28 Unspecified weak opioid 
29 Unspecified simple analgesia 
30 Ketamine  
31 Tramadol 
32  Buscopan 
33 Duloxetine 
34 Pregabalin 
 
Time since treatment (tx) to pain site 
1 >6 weeks 
2 <6 weeks 
3 Current systemic treatment likely to 
reduce pain 
 
Pain Site 
Site of Pain Code 
Lumbar Spine 1 
Thigh 2 
Scapula 3 
Shoulder 4 
Cervical spine 5 
Thoracic Spine 6 
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Sacrum 7 
Groin 8 
Leg 9 
Hip 10 
 Arm 11 
Lower Chest Wall 12 
Upper Chest Wall 13 
Rib 14 
Sacro-Ileac Joint 15 
Other 16 
Buttocks 17 
Foot 18 
Pelvis 19 
Groin 20 
Femur 21 
Tibia/Fibula 22 
Skull 23 
Sternum 24 
Radius/Ulna 25 
Hands 26 
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McGill Pain Descriptors 
Subsections Word Code 
Temporal Flickering 1 
Quivering 2 
Pulsing 3 
Throbbing 4 
Beating 5 
Pounding 6 
Spatial Jumping 7 
Flashing 8 
Shooting 9 
Punctate pressure Pricking 10 
Boring 11 
Drilling 12 
Stabbing 13 
Lancinating 14 
Incisive pressure Sharp 15 
Cutting 16 
Lacerating 17 
Constrictive pressure Pinching 18 
Pressing 19 
Gnawing 20 
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Cramping 21 
Crushing 22 
Traction pressure Tugging 23 
Pulling 24 
Wrenching 25 
Thermal Hot 26 
Burning 27 
Scalding 28 
Searing 29 
Brightness Tingling 30 
Itchy 31 
Smarting 32 
Stinging 33 
Dullness Dull 34 
Sore 35 
Hurting 36 
Aching 37 
Heavy 38 
Misc (sensory) Tender 39 
Taut 40 
Rasping 41 
Splitting 42 
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Tension Tiring 43 
Exhausting 44 
Autonomic Sickening 45 
Suffocating 46 
Fear Fearful 47 
Frightful 48 
Terrifying 49 
Punishment Punishing 50 
Gruelling 51 
Cruel 52 
Vicious 53 
Killing 54 
Misc (Affective) Wretched 55 
Blinding 56 
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Appendix 2 - ECOG Performance status 
 0 – Asymptomatic (Fully active, able to carry on all predisease activities 
without restriction) 
 1 – Symptomatic but completely ambulatory (Restricted in physically 
strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature. For example, light housework, office work) 
 2 – Symptomatic, <50% in bed during the day (Ambulatory and capable of 
all self-care but unable to carry out any work activities. Up and about 
more than 50% of waking hours) 
 3 – Symptomatic, >50% in bed, but not bedbound (Capable of only limited 
self-care, confined to bed or chair 50% or more of waking hours) 
 4 – Bedbound (Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair) 
 5 – Death 
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Appendix 3 - Systematic Review Checklist 
 
Study identification (Include author, title, year of publication, journal title, pages) 
Guideline topic: 
Checklist completed by:  
Section 1:  Internal validity 
1.0 What is the study type Case-control 
RCT 
Intervention 
Intervention 
Review 
Other: 
1.1 Does the paper include CIBP or NCP 
or both 
CIBP  
NCP 
Both 
Neither 
1.2 The study addresses patient 
descriptors of CIBP or NCP 
 
Well covered 
Adequately 
addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.3 A description of the methodology 
used is included 
 
Well covered 
Adequately 
addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.4 Were any assessment tools used eg 
BPI or McGill 
 
1.5 What was the sample size? 
 
Well covered 
Adequately 
addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
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 1.6 Study quality is assessed and taken 
into account. 
 
Well covered 
Adequately 
addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.7 Does this answer key question: verbal 
descriptors of CIBP and NCP? 
 
Yes 
No 
Unsure 
 
SECTION 2:   OVERALL ASSESSMENT OF THE STUDY 
2.1 How well was the study done to 
minimise bias? Code ++, +, or  
 
 
2.2 If coded as +, or  what is the likely 
direction in which bias might affect 
the study results? 
 
2.3 Should this be included in literature 
review? 
Yes                               No                          
Unsure 
2.4 Comments  
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Appendix 4 - SF- McGill Pain Questionnaire 
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